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PREFACE 
 
This thesis details the ensuing major chapters in this thesis with this chapter included.  
Chapter 1:  
This chapter introduces the background of the study, its rationale, relevance and the aims and 
objectives. This chapter also includes the summarized outline of this thesis. 
Chapter 2:  
This chapter unveils a detailed literature appraisal of TB as an epidemic, the co-infection of TB and 
HIV, various experimental techniques for diagnosis TB, TB treatment, highlights of drug resistance 
in TB, Rifampin resistance, insights into current therapeutic approaches for and Rifampin resistance 
and the Mtb RNAP as an anti-TB target for the rational and in silico design of potential inhibitors of 
TB. 
Chapter 3: 
Chapter 3 describes Computer-Aided Drug Design as applied in the studies reported in this thesis. It 
also provides theoretical insights into the various molecular modelling tools and techniques that were 
employed to investigate the various conformational changes, structural conformations  and the impact 
of the induced single active mutation on co-bound and singly bound Mtb RNAP.  
Chapter 4: (Submitted work- this chapter is presented in the required format of the journal 
and is the final revised submitted version) 
This chapter presents results from the study titled “Co-inhibition as a strategic therapeutic approach 
to overcome Rifampin resistance in TB therapy: Atomistic insights”. Article was submitted the 
journal of Future Medicinal Chemistry. 
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Chapter 5: (Submitted work- this chapter is presented in the required format of the journal 
and is the final revised submitted version) 
This chapter presents results from the study titled “Synergistic Interplay of The Co-administration of 
Rifampin And Newly Developed Anti-TB Drug: Could It Be a Promising New Line of TB Therapy?”. 
Article was submitted to the journal of Receptor and Signal Transduction. 
 
Chapter 6: Proposes future work, recommendations, and concluding remarks. 
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ABSTRACT 
 
The impact of Rifampin resistance on the overall global epidemic of antimicrobial resistance has 
become very prominent in recent years and is eventually stifling current efforts being made to control 
tuberculosis drug resistance. Rifampin resistance has significantly contributed to making TB the 
leading cause of morbidity from an infectious disease globally. The  RNA polymerase of 
Mycobacterium tuberculosis has been extensively explored as a therapeutic target for Rifampin 
resistance with recent studies exploring synergistic inhibition as an effective approach, by combining 
Rifampin and other drugs in the TB drug resistance. Apart from the paucity of data elucidating the 
structural mechanism of action of the synergistic interaction between Rifampin and DAAPI, previous 
studies did not also utilize the X-ray crystal structure of Mtb RNAP due its unavailability. 
This thesis used advanced computational tools to unravel molecular insights into the suppression of 
the emergence of resistance to Rifampin by a novel Nα-aroyl-N-aryl-phenylalaninamides (AAPI) 
prototype inhibitor, DAAPI, co-bound to Mtb RNAP with Rifampin. Our studies revealed co-binding 
induced a stable Mtb RNAP protein structure, increased the degree of compactness of binding site 
residues around Rifampin and subsequently improved the binding affinity of Rifampin.  
Studies in this thesis further provide an atomistic mechanism behind Rifampin resistance when the 
recently resolved crystal structure of Mycobacterium tuberculosis RNA polymerase is subjected to a 
single active site mutation. We also identified and rationalized the structural interplay of this single 
active site mutation upon co-binding of Rifampin with the novel inhibitor, DAAPI. Our findings 
report that the mutation distorted the overall conformational landscape of Mycobacterium 
tuberculosis RNA polymerase, resulting in a reduction of binding affinity of Rifampin and an overall 
shift in the residue interaction network of Mycobacterium tuberculosis RNA polymerase and upon 
single binding. Interestingly, co-binding with DAAPI, though impacted by the mutation exhibited 
improved Rifampin binding interactions amidst a distorted residue interaction network. 
Findings establish a structural mechanism by which the novel inhibitor DAAPI stabilizes 
Mycobacterium tuberculosis RNA polymerase upon co-binding with Rifampin, thus suppressing 
Rifampin resistance. We also provide vital conformational dynamics and structural mechanisms of 
mutant enzyme-single ligand and mutant enzyme-dual ligand interactions which could potentially 
xvi 
 
shift the current therapeutic protocol of TB infections, thus aiding in the design of novel 
Mycobacterium tuberculosis RNA polymerase inhibitors with improved therapeutic features against 
the mutant proteins.
  
CHAPTER 1 
1 Introduction 
 
1.1 Background and rational of study 
The studies presented in this thesis is geared towards comprehending and giving molecular insights 
in the recently resolved Mycobacterium tuberculosis (Mtb) RNA Polymerase (RNAP), while 
unraveling the potential of co-inhibition as a solution to the Rifampin resistance in TB treatment. One 
of the major problems in the treatment of TB is the rapid emergence of several drug resistant strains 
[1,2], which leads to the ineffectiveness of several potent anti-TB drugs, such Rifampin [1,3]. Initial 
in silico exploration of the conformational properties of this enzyme and a further investigation of the 
mechanism of drug resistance will provide valuable information in the continuous search for an 
answer to Rifampin resistance and possibly anti-TB drug resistance. These insights will also be 
relevant in the design and development of more potent inhibitors targeting different drug resistant 
strains of Mtb. 
 
Mycobacterium Tuberculosis RNAP has proven over the years to be a viable and efficient target for 
the treatment of TB as it catalyzes a very critical process of RNA transcription by inhibiting the 
elongation of essential nucleotides [4]. However, the unavailability of its x-ray crystal structure 
hampered the efforts of previous in silico studies, since they were mostly based on homology models 
from available crystal structures of related organisms. With the recently resolved Mtb RNAP [5], it 
is strategic to provide molecular insights into the dynamic and structural conformations of this protein 
when exposed to single binding with Rifampin or co-binding with Rifampin and a novel inhibitor. 
 
The suppression of the emergence resistance to Rifampin by a co-administered novel Nα-aroyl-N-
aryl-phenylalaninamides (AAPI) prototype, DAAPI, acting at a separate binding sites on Mtb RNAP, 
as experimentally demonstrated by Lin et al [5], is a very crucial finding towards the search of a 
solution to Rifampin resistance. These novel co-administered drugs elicit their function by binding 
separately from the binding pocket of Rifampin. By inhibiting the activity of Mtb RNAP with a 
mechanism different from that of Rifampin, these novel inhibitors provide an additive antibacterial 
activity, while also suppressing the emergence of resistance to Rifampin [5]. The current treatment 
regimen against RR-TB is based on a cocktail of second-line anti-TB drugs as recommended by the 
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WHO treatment guidelines [6].  The cocktail includes; isoniazid, pyrazinamide, streptomycin, and 
ethambutol and is administered over a period of 9 to 12 months [6,7]. 
 
Molecular modelling techniques have emerged as close complements to experimental studies in 
modern drug discovery process and in the understanding of very complex biological phenomena [8]. 
Various computational tools such as molecular dynamics (MD) simulation and advanced post 
dynamic analysis have played a huge role in precise molecular level understanding of the interaction 
drug molecules to targets. In this thesis, MD simulations and enhanced post analysis techniques e.g. 
Root Mean Square Deviation (RMSD), Root Mean Square Fluctuation (RMSF), Radius of Gyration 
(RoG), Molecular Mechanics energies combined with the Poisson–Boltzmann or Generalized Born 
and Surface area continuum solvation (MM/PBSA and MM/GBSA) based binding free energy 
analysis, Residue Interaction Network (RIN) were employed to understand the detailed molecular 
impact of single active site mutation on the binding landscape of Rifampin amidst single and co-
binding with DAAPI and to also unveil the molecular and structural and conformations of single and 
co-binding of both Rifampin and DAAPI on Mtb RNAP. 
1.2 Aims and objectives of this study 
Studies reported in this thesis has two distinct aims. 
• To explore the molecular insights into the suppression of the emergence of resistance of 
Rifampin by a novel Nα-aroyl-N-aryl-phenylalaninamides (AAPI) prototype inhibitor co-
bound to Mtb RNAP with Rifampin, through the accurate probing of the molecular dynamics 
and conformational changes of Mtb RNAP. To achieve this, we; 
o Perform MD simulations on unbound Mtb RNAP, complex of Mtb RNAP with both 
Rifampin  and DAAPI, complex of Mtb RNAP and Rifampin and complex of Mtb RNAP 
and complex of Mtb RNAP and DAAPI in four different systems (APO, RIFDAAPI, 
RIF and DAAPI) 
o Calculate the binding free energy of Rifampin  and DAAPI when they are each singly 
bound and when co-bound to Mtb RNAP  
o Characterize the binding landscape of Mtb RNAP and its structural alteration when 
bound to Rifampin and DAAPI simultaneously 
o Perform per-residue based decomposition for the active site residues of Rifampin and 
DAAPI. 
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• To understand the molecular impact of a single active site amino acid mutation on Mtb RNAP 
on the binding of Rifampin and the novel AAPI prototype. To achieve this aim, we; 
o Generate a mutant Mtb RNAP by substituting serine 429 with leucine at the active site of 
Rifampin using Chimera 
o Perform MD simulations on the following systems;  complex of  mutant Mtb RNAP with 
Rifampin alone, complex of mutant Mtb RNAP with both Rifampin and DAAPI, 
complex of  wild Mtb RNAP with Rifampin only and complex of wild Mtb RNAP with 
both Rifampin and DAAPI (mRIF, mRIFDAAPI, RIF, RIFDAAPI)   
o Investigate the general stability of the various system throughout the simulation period 
o Investigate the stability the various simulated systems during the across the simulation 
period 
o Perform the multiple post dynamics analyses coupled with MM/GBSA based binding 
free energy calculation to understand the effect of the mutation 
o Perform and explore the residue interaction network of Mtb RNAP amidst single active 
site mutation and co-binding with more Rifampin and DAAPI  
o Perform hydrogen bond analyses on simulated systems. 
 
1.3 Novelty and significance of study 
The crystallization of the protein structure of Mtb RNAP was recently reported by Lin et al [5]. There 
has been no evidence of Mtb RNAP crystal structure prior to this report. As a result, all previous in 
silico studies on Mtb RNAP have been based on homology models or from closely related structures 
like the RNAP of Escherichia coli [9,10]. These crystal structures usually denote a single snapshot 
of the many possible conformations of the enzyme hence portraying a stiff view of the position of the 
atoms that are normally partly agitated by crystal packing. The conformational dynamics of Mtb 
RNAP is yet to be explored per our knowledge. With crystallographic structures representing only a 
specific snapshot of many possible conformations, probing of several crystal structures of the enzyme 
would provide important insights into the dynamic motions that should occur between varying 
conformations. Even though crystallographic B-factors indicate the true static or dynamic mobility 
of residues [11], it is still difficult to infer the precise dynamic features of protein structures. The 
recent resolving of the Mtb RNAP X-ray crystal structure of Mtb RNAP makes it strategic to perform 
molecular dynamic simulations since this provides a robust tool to understand the conformational 
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landscape of the enzyme. In a recent report, the possibility of a novel Mtb RNAP-targeting inhibitor 
to suppress the emergence of resistance to Rifampin was experimentally predicted [5]. However, in 
silico techniques to explore the molecular insights into this possibility is yet to be explored Using 
sophisticated molecular techniques, this study reports the first account of the conformational 
dynamics of the first crystal structure of Mtb RNAP unbound and upon co-binding with both 
Rifampin and the novel AAPI inhibitor, DAAPI. We will also provide insights into the understanding 
of the mechanism of  Rifampin resistance  by unveiling the impact of single active site mutation on 
the binding affinity of Rifampin and DAAPI amidst single binding or co-binding. This should provide 
an invaluable contribution to the design of potent inhibitors targeting Mtb RNAP. 
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 CHAPTER 2 
2 Background on the etiological agent of tuberculosis 
 
2.1 Introduction 
Tuberculosis (TB) is an infectious disease caused by Mycobacterium Tuberculosis (Mtb) [1,2]. 
Despite the availability of well-structured treatment options, a functional vaccine and an overall 
resultant cure, tuberculosis is still a major global health concern [1,2]. As discovered and reported by 
Robert Koch in 1882, TB is an airborne infectious disease caused by organisms of the Mtb complex 
[2–4]. Most of the reported TB cases have been caused by Mtb or the closely related Mycobacterium 
africanum, even though there are few reported cases in which  zoonotic members of the complex such 
as Mycobacterium bovis or Mycobacterium caprae also cause the disease [5]. However, it is important 
to note that Mtb has no other known environmental reservoir apart from humans [6] probably 
accounting for being the highest causative agent of the TB disease amongst the Mtb complex. 
Clinically, TB patients have been classified as having a latent TB infection (LTBI) or and an active 
TB disease.  In Latent tuberculosis infection, there is no evidence of clinically manifested active TB 
amidst persistent response of the immune system to Mtb antigen stimulation [7–9]. Individuals with 
LTBI risk development of active TB disease by a process of TB reactivation, especially in 
immunocompromised conditions such as Human Immunodeficiency Virus/Acquired Immune 
Deficiency Syndrome (HIV/AIDS), whose risk is much higher [8]. It is estimated that about one third 
of the world population has LTBI, of which many are oblivious for their condition. Active TB disease 
begins when Mtb overcomes an individual’s immune defense system. This results in the 
multiplication of the bacteria and eventual progression of LTBI to the active TB disease [7].  
2.2 TB incidence 
TB is currently ranked above HIV/AIDS as the leading cause of morbidity from an infectious disease 
and still features prominently in the top ten causes of death worldwide [1]. Over the years, TB has 
proven to be a disease of the poor with highest prevalence being in developing countries with 
predominantly low-income and middle-income populations [1,10,11]. According to the 2017 global 
TB report, about 10.4 million new cases of TB were recorded worldwide in 2016 with 45% occurring 
in the World Health Organization (WHO) South-East Asia Region, 25% in WHO African Region, 
17% in WHO Western Pacific Region, 7% in WHO Eastern Mediterranean Region, 3% in the 
European Region and an estimated 3% in the WHO Region of the Americas. In 2016, countries with 
the largest number of incident cases included India, China, Philippines, Indonesia and Pakistan, which 
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collectively accounted for 56% of total global incidence whiles South Africa and Nigeria each 
accounted for 4% each [1]. 
South Africa retains its position as one of the countries with the leading TB burden globally with an 
estimated 428,000 total TB incidence in 2016 [1]. This has been complicated by the notable high HIV 
prevalence in South Africa  as with an increase in the reported TB and HIV co-infection cases [1]. 
 
 
Figure 2.1 Estimated TB incidence rates from the 2017 Global TB reports [1]. 
2.3 TB and HIV  
People living with HIV has accounted for 10% of all new TB cases, with  countries in the WHO 
Africa Region accounting for the highest co-infection estimates globally [1]. Parts of Southern Africa 
recorded an over 50% of new TB and HIV cases. The WHO African Region reportedly has the highest 
burden of HIV-associated TB, with 81% of notified infected individuals having a previously 
documented HIV test report [1]. The percentage of known HIV-positive TB patients on anti-retroviral 
therapy exceeds 90% in India, Malawi, Kenya, Namibia, Swaziland and Mozambique [1]. Co-
infection with TB and HIV collectively constitute the leading cause of morbidity from infectious 
diseases. There is a rapid deterioration of an individual’s immune defense mechanism in the presence 
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of these two pathogens since they potentiate each other, thereby resulting in premature deaths [12]. 
Together with drug resistance, the co-infection of TB and HIV hampered global TB control efforts 
most especially in high burden areas such as sub-Saharan Africa [13,14]. In South Africa, it is 
reported that approximately 70% of persons infected with active TB disease are simultaneously 
infected with HIV [15]. Co-infection of TB with HIV single handedly incresed the reactivation of 
LTBI by 20 fold [16,17]. 
 
 
Figure 2.2 Estimated HIV prevalence in new and relapse TB cases from the 2017 Global TB report 
[1]. 
 
2.4 Mode of Transmission 
Aerosols containing Mtb from an infected person serves as the main route of transmission. Upon the 
entry, Mtb targets alveoli of host lungs [12,18,19]. In response, macrophages and other immune cells 
are assembled by host during this early stage of the infection [20]. Even though Mtb can infect other 
body organs and tissues such as the spine, the brain and the kidney [21,22],  Mtb commonly settles in 
the lungs characterized by symptoms such as such as weight loss, loss of appetite, night sweats, 
9 
 
coughing of sputum and/or blood, fever, fatigue and chills [1,18,23]. Depending on an individual’s 
immune system, Mtb in an infected individual can be classified as latent TB (inactive) or become 
active and referred to as TB disease [23]. The re-emergence of TB in a previously infected individual 
may be triggered by factors such as smoking, immunosuppression, alcohol, genetic factors, HIV 
infection and indoor air pollution [18,23]. 
 
 
2.5 Diagnosis of Tuberculosis & Drug Susceptibility Testing  
The management of TB is enhanced by early diagnosis of the infection and the performance of drug 
susceptibility testing [24]. Sputum smear microscopy and culture based technology remain a vital 
technique in the diagnosis of TB [25]. The Ziehl-Neelson (ZN) staining technique is used in the 
detection of Mtb [25,26]. The principle behind this technique is based on the differential acid fast 
staining property of the Mtb due to the mycolic acid structure of the bacterial cell [25]. Smears of 
sputum are prepared on glass slides. Dried smears are then stained with phenol fuschin [25]. The 
smear is then decolorized using acid alcohol [25]. The decolorized smear is then counterstained with 
either Methylene or malachite green [25]. Alternatively, Auramine-rhodamine staining can be used 
in place of the ZN stain [25]. After decolorization with acid alcohol, Auramine-rhodamine staining 
protocol counterstains with potassium permanganate. Using UV illumination, the fluorescence of 
stained bacteria can then be viewed [27].  
 
Bacterial culture is a sensitive and specific approach for the diagnosis of bacterial infections such as 
TB [26]. The culture of bacteria requires appropriate media for the growth of the organism, which 
can either be solid or liquid [26]. The commonly used media for the growth of Mtb are; Lowenstein-
Jensen (LJ); Middlebrook 7H10/11 and Middlebrook 7H9, a liquid media [28]. For growth and 
isolation, bacterial cultures usually require a period of 3-6 weeks [29]. Currently the reference media 
for the culture of Mtb is the liquid media. The liquid media is linked with higher recovery of the 
tubercle bacilli coupled with a faster detection time [30]. Diagnostic tools such as the BACTEC 
(Johnson Laboratories) and BACTEC-MGIT (Johnson Laboratories) employs colorimetric systems 
for culture based assays and have reportedly improved detection time of the tubercle bacilli of Mtb 
[29]. 
 
 A recently introduced tool,  the Xpert MDR/RIF (Cepheid) assay, incorporates polymerase chain 
reaction (PCR) and molecular beacon technology to yield a significantly higher mycobacterial 
10 
 
sensitivity than sputum smear microscopy [31]. Apart from rapidly diagnosing TB, this fully 
automated technique simultaneously detects Rifampin resistance as well, thereby allowing for early 
treatment of drug resistant TB while awaiting corroboration from drug susceptibility testing, the gold 
standard for the phenotypic determination of drug resistance [31].  
 
2.6 Tuberculosis treatment 
The battle against this killer bacteria begun many decades ago with discovery of potent antibiotics 
against it, the first being streptomycin in 1943 [32]. This served as a stepping-stone for many other 
studies leading to the discovery of the current therapeutic regimens such as rifampicin in 1963  among 
many others, which are available for clinical use now [33,34]. Most of these antibiotics target various 
structural components of the Mtb. They act by inhibiting the synthesis of critical structures required 
for the maturation of Mtb, with the eventual aim of eliminating Mtb [34]. TB-targeted drug agents are 
designed to either inhibit; cell wall biosynthesis, RNA synthesis or protein synthesis [35]. For 
instance the first-line anti-TB drugs, Isoniazide, acts by inhibiting the biosynthesis of mycolic acids, 
essential components of the cell wall of Mtb [36], while Rifampin interferes with the synthesis of a 
DNA-dependent  RNA by inhibiting the activity of the DNA-dependent RNA polymerase enzyme 
[35]. Also, second-line injectables which are mainly aminoglycosides function by blocking the 
initiation of protein synthesis in Mtb [37], while fluoroquinolones inhibit the activity of the enzymes 
DNA gyrase and topoisomerase IV which results in the death of Mtb [38]. 
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Table 2.1: Current TB treatment regimens according to World Health Organisation [39]. 
Group 1: 
First-line oral agents 
Isoniazid; rifampicin; ethambutol; pyrazinamide 
Group 2: 
Injectable agents 
Kanamycin; amikacin; capreomycin; 
streptomycin 
Group 3: 
Fluoroquinolones ofloxacin 
Levofloxacin; moxifloxacin; gatifloxacin 
Group 4: 
Oral bacteriostatic second-line 
agents 
P-aminosalicylic acid; cycloserine; terizidone; 
ethionamide; protionamide 
Group 5: 
Agents with unclear efficacy 
Clofazimine; linezolid; amoxicillin; imipenem; 
clarithromycin; thioacetazone; bedaquiline; 
delamanid; meropenem; high dose of isoniazid; 
 
Currently approved first line antibiotics for drug-susceptible Mtb include rifampin (RIF), isoniazid 
(INH), pyrazinamide (PZA) and ethambutol (EMB) mostly administered over a period of six months 
[40,41]. Provided an infected person follows through the prescribed treatment course, the current 
standard first line antibiotic treatment regimen is effective enough to ensure the clearance bacterial 
bacilli [42]. However, the long-term treatment periods associated with first and second line anti-TB 
agents has resulted in the emergence of Mtb strains that are resist to these anti-TB drugs [43,44]. In 
addition to the first line antibiotic treatment regimen against Mtb, there are four other groups [33]. 
 
2.7 Drug resistance in TB 
Upon the discovery of these many potent antibiotics against the bacteria, there was a general 
excitement within scientific community since these proved to be very effective and provided a 
functional cure. However, this excitement was short lived when there were reports of resistance of 
Mtb to antibiotics [45–47]. Unfortunately, drug resistance has persisted till now and has gotten to a 
point where it poses a major challenge to disease control globally [48,49]. Drug resistance in TB 
treatment has compounded the already grave TB control challenge, with infected persons having to 
go through a prolonged, expensive and limited treatment course, with a risk of about 10-30% of these 
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cases resulting in treatment failure and death [50]. Drug resistance by Mtb is usually associated with 
spontaneous and random bacteria chromosomal mutation that renders Mtb unsusceptible to specific 
anti-TB agents [51]. Several genes have been implicated in TB resistance as illustrated in the table 
below with the corresponding drugs involved. 
 
Table 2.2: List of Anti-TB agents and their corresponding enzyme targets [52]. 
Drug  Genes (s) implicated in resistance 
Rifampin rpoB: b-subnit of RNA polymerase  
Isoniazide katG: catalase-peroxidase 
oxyR-ahpC: alkylhydrokinase reductase 
inhA: enoyl-ACP redactase 
kasA: b-ketoacyl acyl carrier protein synthase 
Ethionamide inhA: enoyl-ACP reductase 
Streptomycin rpsl: ribosomal protein S12 involved in : 16S RNA 
Fluoroquinolones gyrA: DNA gyrase 
Pyrazinamide pncA: pyrazinamidase 
Ethambutol  embCAB: Arabinosyl transferase 
 
Resistance of Mtb to at least two of the most efficacious front treatment regimen, Rifampin and 
Isoniazide has been classified by WHO as Multidrug-resistant Tuberculosis (MDR-TB) [1]. The 2017 
Global TB report reported an estimated 490 000 new MDR-TB cases in 2016 alone, with an estimated 
100 000 confirmed  cases of Rifampicin-resistant TB (RR-TB) [1]. Conferring with the numerous 
studies that have reported primary resistance as a major contributor to the increase of MDR-TB in 
South Africa [53–57], an estimated 19,000 new TB cases in 2016 were attributed to MDR-TB. 
Over time, there has also been the emergence of the Mtb, not only resistant to Rifampin and Isoniazide 
but also resistant to any fluoroquinolone and at least one of the second-line injectables (amikacin, 
kanamycin and capreomycin) which have been classified as extensively drug resistance tuberculosis 
(XDR-TB) [30,58]. XDR-TB  discovered in 2006 in South Africa [59], reportedly has higher 
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incidence rates than  the total TB burden in some low incidence areas such the United States of 
America [60]. More recently, there has also been reports of resistance to all first and second line TB 
drugs described as totally drug resistant TB (TDR-TB) [61]. General treatment timelines for MDR 
TB ranges from 18–24 months with weak second-line TB drugs [62,63]. According to a 2009 report 
by the National Health Laboratory Services in South Africa,  majority of reported MDR-TB and 
XDR-TB cases occur in KwaZulu-Natal, Western Cape and Eastern Cape Provinces [64]. 
 
2.7.1 Rifampin Resistance 
Rifampin resistance contributes significantly to the overall TB drug resistance menace [50]. Rifampin 
resistant TB (RR-TB) occurs as a result of point mutations, nucleotide deletions or insertions in an 
81—base pair region of the rpoB gene [65,66]. The rpoB gene codes for the ȕ-subunit of DNA-
dependent RNA polymerase [67]. Approximately 95% of all  reported Rifampin resistant isolates 
exhibit a single mutation in this 81-base region of rpoB [68]. Mutations usually occur in a cluster of 
codons ranging from 507 to 533 of the rpoB gene, a region also known as the Rifampin resistance-
determining region (RRDR). Mutations on codons 526 and 531 are the most common implicated 
codons in RR-TB [43,44]. Nonetheless, there have been reports of RR-TB resulting from mutations 
occurring outside the RRDR [69]. Rifampin resistance though very rare, is used as a marker MDR-
TB since it usually occurs in concurrence with isoniazid [58,70]. 
 
2.8 Explored anti-TB Resistance remedies  
Bedeviled with the challenge of the various types of drug resistance, there has been the need for the 
development of innovative treatment protocols to curtail the continuous rise of TB fatalities resulting 
from TB resistance. Combinational therapeutic methods came in as one of the options, in which 
several antimicrobial drugs have been combined over the years towards the treatment of TB [71,72].  
In 1950, the British Medical Journal reported of the first combinational antimicrobial therapeutic 
regimen for TB involving para-aminosalicylic acid and streptomycin, which served as a model from 
which new drugs were subsequently discovered [73]. This was again re-echoed by Fox et al in 1999 
[74]. Combining drugs for the treatment of TB has subsequently proven to be very effective method 
of suppressing the emergence of drug resistance in active Mtb infection after its first application [75]. 
However, it is important to recognize that, the overall efficacy depends largely on choosing the right 
drugs to combine as well as the receptor that will be targeted [73]. It is however unfortunate that 
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despite the success of combinational therapy over the years, Mtb drug resistance is still a global 
concern, mostly due to the emergence of resistant strains [55]. These strains are shown to exhibit 
point mutations at binding sites of known TB drugs, altering the binding affinity of these potent drug 
and hence their efficacy [76–78]. 
Treatment of RR-TB usually involves an increase in duration of therapy to about 9 to 12 months from 
the initial 6 months due to its associated with poorer clinical outcomes [50,79,80]. A therapeutic 
cocktail of second line agents are recommended for the treatment of RR-TB as stipulated in the WHO 
guidelines [50]. Streptomycin, isoniazid, ethambutol and pyrazinamide  over a period of 9 months 
can be used to treat isolated cases of RR-TB [81]. 
 
2.9 Mycobacterium Tuberculosis RNA Polymerase as an anti-TB target 
One of the major enzymes that have been targeted in the discovery of anti-TB drugs is the DNA-
dependent RNA polymerase (RNAP) [72]. It is the target enzyme for the frontline line anti-TB drug 
Rifampin, an antibiotic which has proven over the years to be very essential in anti-TB therapeutic 
protocols [50,72,82–84]. RNAP has been widely reported to exist in two forms, an RNAP core and 
RNAP holo [85–88]. According to studies by Rodrigue et al in 2006 and 2007, Manganelli et al in 
2004, the RNAP is involved in the catalysis of RNA synthesis, however, it is incapable of starting 
transcription from a promoter. Therefore, RNAP would require a factor called σA holoenzyme for 
promoter specific transcription initiation. Even though RNAP has been an effective target for 
Rifampin, Mtb has been reported to have developed resistance to Rifampin [77]. Rifampin resistance 
has gradually become a global health concern with as many as 600,000 new cases annually [50,72,84]. 
Therefore, to target RNAP any further for potential anti-TB inhibitors, there was the need to consider 
either Rifampin derivatives that were unaffected by the current Rifampin binding site or developing 
entirely new inhibitors that were not linked to Rifampin at all and function by binding to a separate 
binding site on RNAP, hence not affected by any substitutions in the Rifampin binding site [84]. This 
has however been challenging due to the previous unavailability of an X-ray crystal structure of Mtb 
RNAP, until they were recently reported [89]. 
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Figure 2.3: Crystal structure of Mtb RNAP showing the various subunits (A), single binding with 
Rifampin alone (B) and co-binding with both Rifampin and DAAPI (C). 
 
Over the years several crystal structures of Mtb RNAP have been resolved and deposited in the Protein 
Data Bank. However, the continuous inundation of the scientific community with new findings on 
Mtb RNAP has prompted the resolving of new crystal structures. These structures incorporate the 
most recent experimentally validated fundamental characteristics and unveiled new structural features 
in the enzyme, which can serve as the basis for rational drug design. 
Lin et al recently reported the first ever X-ray crystal structure of the DNA-dependent enzyme RNA 
polymerase enzyme of Mtb, in its wild type, in complex with Rifampin (a known frontline anti-TB 
drug), in complex with DAAP1 (a prototype class from set of novel of inhibitors called Nα-aroyl-N-
aryl-phenylalaninamides (AAPs) and in complex with both Rifampin and DAAP1 [89]. This novel 
prototype class (DAAP1) was reported to exhibits potent, selective, stereospecific activity against 
Mycobacterial RNAP [89]. This novel inhibitor also exhibit potent, selective and stereospecific 
activity against Mycobacteria, notably Mtb, Mycobacterium smegmatis and Mycobaterium avium 
[89]. 
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Table 2.3: Recently resolved X-ray of Mtb RNAP structures. 
X-ray Crystal 
Structure 
Resolution   
(Å) 
Ligand/Inhibitor PDB 
Entry 
Reference, Date 
of publication 
Mtb transition 
initiation complex 
3.9 Zn, Mg 5UHA Lin et al (Jan 2017) 
Mtb transition 
initiation complex 
with Rifampin 
4.29 Zn, Mg, Rifampin 5UHB Lin et al (Jan 2017) 
Mtb transition 
initiation complex 
containing 3nt RNA 
in complex with 
Rifampin 
3.8 Zn, Mg, Rifampin 5UHC Lin et al (Jan 2017) 
Mtb transition 
initiation complex 
containing 4nt RNA 
in complex with 
Rifampin 
4.01 Zn, Mg, Rifampin 5UHD Lin et al (Jan 2017) 
Mtb transition 
initiation complex 
with D-AAP1 
4.04 Zn, Mg, Nalpha-
(benzenecarbonyl)-
N-(2-
methylphenyl)- D-
phenylalaninamide 
5UHG Lin et al (Jan 2017) 
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Mtb transcription 
initiation complex in 
complex with D-
IX336 
 
4.34 Zn, Mg, N-(2-
methylphenyl)-
Nalpha-
(selenophene-2- 
carbonyl)-D-
phenylalaninamide 
5UHF Lin et al (Jan 2017) 
Mtb tuberculosis 
transcription 
initiation complex in 
complex with D-
AAP1 and Rifampin 
 
3.97 Zn, Mg, N-(2-
methylphenyl)-
Nalpha-
(selenophene-2- 
carbonyl)-D-
phenylalaninamide, 
Rifampin 
5UHG Lin et al (Jan 2017) 
Mtb transcription 
initiation complex 
containing 3 nt of 
RNA 
 
3.75 Zn, Mg 5UH5 Lin et al (Jan 2017) 
Mtb transcription 
initiation complex 
containing 2ntRNA 
in complex with 
Rifampin 
 
3.84 Zn, Mg, Rifampin 5UH6 Lin et al (Jan 2017) 
Beta'MtbSI of 
Mycobacterium 
2.2 No ligand/inhibitor 5UH7 Lin et al (Jan 2017) 
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tuberculosis RNA 
polymerase 
 
Mtb transcription 
initiation complex 
containing 4nt RNA 
 
4.18 Zn, Mg 5UH8 Lin et al (Jan 2017) 
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CHAPTER 3 
3 Introduction to computational chemistry and molecular modelling  
3.1 Introduction 
Computational chemistry is a sub-specialty of chemistry. It is also referred to as molecular modelling. 
It incorporates computational techniques to investigate and analyze biochemical or chemical 
problems from an atomistic and molecular viewpoint. Computational chemistry investigates the 
three-dimensional molecular structure, molecular dynamics and flexibility, physical properties and 
biological activities such as protein folding, stability and conformation of biological molecules. 
Computational research generates data that augments experimental studies using techniques that are 
less expensive and generates results within a shorter time frame. As a result, molecular modelling has 
been prominent in recent years in the discovery, design and development of new drug molecules. It 
increases the effectiveness of rational drug design process by feeding on the findings of experimental 
research to generate lead compounds and giving insights into their possible adverse effects. Of the 
three basic computational chemistry methods, molecular dynamics was largely employed in the 
research for this thesis. Molecular dynamics gave insights on the conformational insights of 
macromolecules interacting with small molecules bound to it. This chapter mainly describes the 
computational theories that support molecular mechanics, molecular dynamics and post analytic tools 
as applied in this present study.  
 
3.2 Quantum Mechanics 
Quantum mechanics is a branch of classical physics that defines molecules based on interactions 
between nuclei and electrons, and molecular geometry in terms of minimum energy arrangements of 
nuclei [1,2]. Using wave functions, quantum mechanics describes microscopic systems by completely 
characterizing all the physical properties of the system [2].  Nuclei and corresponding electrons of 
the systems are arranged in a three-dimensional space [2]. The electrons are then mapped using the 
continuous electronic density method and the energetics measured is solved by the Schrödinger 
equation [2].  
26 
 
3.2.1 The Schrödinger Wave Equation 
The Schrödinger equation forms the bases of all approximations in quantum mechanics [3]. The 
equation is based on a model of an atom that was proposed by Erwin Schrödinger an Austrian 
physician in 1926, in which he used mathematical equations to describe the probability of locating an 
electron at an exact path [3]. In expanding on Neil Bohr’s atom model, Schrödinger  depicted the 
model as a nucleus that is surrounded by an electron cloud of high and low densities [2,4].  
Schrödinger was able to postulate an energy relationship of the time independent wave equation by 
merging the classical differential equation which defines the profile of a simple harmonic standing 
wave and the De’Broglie’s relation between matter and waves [4] . There is also a time dependent 
Schrödinger  equation [1,5] which is the largely used one of the two. It defines the Hamiltonian 
operator as the sum of the kinetic energy and the potential energy. The general forms of the 
Schrödinger  equation is as follows: 
                 �� = ણ�               (Eq. 3.2.1.1) 
 
Where, Η denotes the Hamiltonian operator, Ψ denotes the wave function (or eigenfunction) and E, 
denoting the energy of the system also referred to as the operator energy eigen value [2,5]. This 
description is a probabilistic description of electron behavior. In order to replicate a relevant physical 
model of Schrödinger’s equation, the wave function must be continuous, normalizable single valued 
and antisymmetric relative to electrons interchange [6]. The molecular Hamiltonian operator is 
derived from the sum of the atom’s total potential energy (V) and the kinetic energy (T) represented 
as: 
  � = ࢂ + ࢀ                              (Eq. 3.2.1.2) 
When considering particles as point masses, while neglecting relativistic effects, the Hamiltonian will 
therefore constitute all the kinetic and potential energy operators for all the electrons and nuclei in a 
molecule. An advanced Hamiltonian  is mathematically expressed as follows: 
� = [− ࢎ૛��૛ ∑࢏ ૚࢓࢐ ቀ �૛�࢞૛ + �૛�࢟૛ + �૛�ࢠ૛ቁ + ∑࢏∑ < ࢐ (ࢋ࢏ࢋ࢏࢘࢏࢐ )]                                                        (Eq. 3.2.1.3) 
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 Involving a multitude of mathematical equations, the Schrödinger equation is unable to be solved for 
a molecular system whose number of atoms may range in thousands [7–9]. A compensation for this 
challenge for molecular systems is the Born-Oppenheimer approximation 
 
3.2.2 Born-Oppenheimer Approximation 
The Born-Oppenheimer Approximation addresses the challenges and limitations of the Schrödinger 
equation as a result; it is one of the most essential approximations in molecular quantum mechanics 
[10]. The Born-Oppenheimer Approximation relies on the assumption that the motion of electrons 
and nuclei can be separated [11]. It was developed by Max Born and J. Robert Oppenheimer in 1927 
after the publication of the Schrödinger equation, to illustrate how the nuclear motion in a molecule 
can be determined as a function of its electronic motion [11] . This approximation permits the 
Schrödinger’s equation to be divided and expressed as an ‘electronic’ equation and a nuclear equation. 
Electrons have a lighter weight than nuclei; as a result, they have an increased velocity [10]. The 
difference in weight between the electrons and nuclei is accounted for by the Born-Oppenheimer 
approximation, and based on this difference, the electrons can therefore almost instantaneously 
respond to nuclei displacement [11]. Distribution of electrons within a molecular system is therefore 
defined by the location of the nuclei [12,13]. Hence as an alternative to solving the Schrödinger 
equation for every particle at the same time, the nuclear kinetic energy operator is ignored due to the 
fixed position of the nuclei while the equation is solved for electrons in the static electrical potential 
that arises from the nuclei in that arrangement [13–15].  
 
The difference in velocities of the nuclei and electrons allow for the Born-Oppenheimer 
approximation to be applied, minimizing the complexity of the wave function of the Hamiltonian 
equation [15]. The simplified wave function of the Hamiltonian is mentioned as below: 
 
  � = − ࢎ૛૛࢓ࢋ ∑࢏�࢏૛ −  ࢎ૛૛ ∑� ૚ࡹ࡭ �࡭૛ − ∑�∑࢏ ࢋ૛࡭�࢘࡭࢏ + ∑࢏∑࢐>࢏ ࢋ૛࢘࢏࢐ + ∑࡭∑࡮>࡭ ࢠ࡭�࡮ࢋ૛ࡾ࡭࡮                 (Eq. 3.2.2.1) 
 
Where A and B denotes the nuclei, while i and j represent  the electrons. MA represents the nucleus 
A mass while me denotes an electron mass. RAB represents a nuclei A and B inter-distance with rij 
being the distance between i and j electrons.  ZA is nucleus A charge while rAi represents nucleus A 
and electron i inter-distance.  
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Born-Oppenheimer approximation when applied minimizes the complexity of the Hamiltonian and 
the wave function due to differences between electron and nuclei velocities [14]. The instantaneous 
response of electrons to nuclear motions results in the wave simplified as follows: 
 
 � ሺ࢘ࢋ࢒ࢋࢉሻ = �ሺ࢘ࢋ࢒ࢋࢉሻሺ࢘࢔࢛ࢉ࢒ሻ                                                                       (Eq. 3.2.2.2) 
 
Which is subsequently changed to 
 ����ሺ࢘ࢋ࢒ሻ = ����ሺ࢘ࢋ࢒ሻ                                                                                         (Eq. 3.2.2.3) 
 
Where HEN symbolizes a difference between terms based on their dependence on fixed nuclear 
positions (VNN) or their dependence on the non-fixed electron positions (Hel).  An energy term EEN is 
integrated which is derived from two sources; one being the fluctuating electron co-ordinates E and 
fixed nuclear co-ordinates N: 
 
 �ࢋ࢒ + ࢂࡺࡺሻ �ሺ࢘ࢋ࢒ሻ = ����ሺ࢘ࢋ࢒ሻ                                                                               (Eq. 3.2.2.4) 
 
It is important to note that Born-Oppenheimer approximation exhibits more accuracy when applied 
to electrons in ground states rather than those in excited states [2,10]. Upon solving the equation, it 
enables the construction of molecular potential energy curve and a potential energy surface of a 
polyatomic molecule [10]. It also allows for the identification and assessment of the equilibrated 
conformations for a given molecule with the lowest point on the surface [10,15]. 
 
3.2.3 Potential Energy Function 
As a mathematical function, potential energy surface graphically portrays the energy of a molecule 
as a function of its geometry [16]. Thus it determines the vibrational motion of molecules relative to 
the position of the nuclei in a chemical reaction [16]. The concept of potential energy stems from the 
Born-Oppenheimer approximation in which variations in mass and magnitude of the velocity between 
electrons and nuclei is understood as the potential of atoms movement within a molecule which 
collide with each other, referred to as the adiabatic motion [15,16].  As displayed in the figure below, 
high potential energy regions display specifies a high-energy nuclear arrangements or molecular 
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conformations and whereas a low energy regions signifies low nuclear energy conformation and can 
be applied in computational chemistry for this purpose [2]. 
 
 
Figure 3.1: A graphical representation of a two-dimensional potential energy surface [17]. 
 
3.3 Molecular Mechanics 
Molecular mechanics (MM) enables the molecular dynamics computations on large molecules by 
incorporating potential energy [18]. In modelling molecular systems, MM applies coulomb potential 
or harmonic oscillator [2,19]. It describes the molecular systems in bonded atoms, which have been 
distorted from some idealized geometry due to nonbonded van der Waals and Coulombic interactions 
[5,21]. MM incorporates a classical type models to predict the energy of a molecule as a function of 
its conformation [5]. By so doing, it enables the predictions of equilibrium geometries and transition 
states and also allows the prediction of relative energies between conformers or between different 
molecules [5]. As an alternative to quantum mechanics, MM are the methods of choice for protein 
simulations and adheres to the Newtonian laws of classical mechanisms and are essential in the study 
of conformational flexibility [19]. MM expresses  the energy of a molecule as a function of its 
resistance toward bond stretching,  atom crowding and bond bending and to use this energy equation 
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to find the bond angles, lengths and dihedrals corresponding to the minimum-energy geometry – or 
more precisely, to the various probable potential energy surface minima [21,22]. Nonetheless MM 
are appropriate for bond-breaking reactions just like most ab initio methods [23]. MM or the force-
field method is mathematically described as follows; 
         
 
             �࢚࢕࢚ = �࢙࢚࢘ + �࢈ࢋ࢔ࢊ + �࢚࢕࢙࢘ + �࢜ࢊ࢝ + �ࢋ࢒ࢋࢉ                                                        (Eq. 3.3.1) 
 
Where, 
Etot  = total energy,                                 Estr =  bond-stretching energy, 
Ebend = angle-bending energy               ,Etors = torsional energy,      
Evdw = van der Waals energy             Eelec = electrostatic energy.  
 
 
Figure 3.2: Diagrammatical depiction of bonded and non-bonded interactions acting in molecular 
motion [24]. 
 
31 
 
3.4 Quantum Mechanics/Molecular Mechanics (QM/MM) 
Most recently, the combination of both quantum mechanical and molecular mechanical methods 
[25,26] to form a hybrid of the two has rapidly gained prominence as a viable approach for the study 
biomolecular mechanisms [26–28]. The underlining postulation that bonds are never created or 
broken renders MM inappropriate for studying the mechanisms of reaction for biomolecular systems 
[30]. QM methods on the other hand have huge computational cost, exhaustive, making calculations 
on the scale of entire solvated proteins currently obstinate [30,31]. QM/MM as a hybrid concept 
basically employs algorithms that blend the description accuracy of QM and the characteristic low 
computational cost of MM [32]. The technique of QM/MM encompasses two steps-wise domains, a 
QM and an MM phase [33]. In the QM phase, the reactive domain, which includes ligands and amino 
acids, are treated with QM techniques, which defines the electronic structures of molecules [32]. This 
MM phase defines interactions between atoms by incorporating a force field which acts as a potential 
energy function [31,34]. Amidst the notable advantages of hybrid QM/MM method over QM and 
MM, it may not be appropriate for every structure-based drug design study; hence further exploration 
of the technique may be required [32]. 
 
Figure 3.3: Characterization of the QM/MM components. 
 
32 
 
3.5 Force-Fields 
Force fields for MD simulations should be compatible with biomolecules or at least proteins that are 
enclosed in a biologically relevant environment like an aqueous solution, must support drug-like 
molecules in solution phase and should be explicitly parameterized to reproduce intermolecular 
interaction [19]. As a mathematical function with set parameters, a force field can be used to describe 
the energy associated with the conformation of molecule [35]. The force field used to parameterize 
the Mtb RNAP protein in the studies reported in this thesis is the AMBER [36] force field whiles the 
GAFF were also used to interpret the ligands. Other commonly used force fields include CHARMM 
[37], GROMOS [38], OPLS-AA [39] and ENCAD [40,41]. Most force fields applied in MD 
simulation of proteins are harmonic motions in nature, along with a describption of  bond lengths and 
angles [35]. The main variations between the various force fields result come from the varied 
approaches to obtain the individual parameters, however, they largely yield similar findings which 
corroborate with experimental results [42]. 
 
3.6 Molecular Dynamics 
Over the year’s biological assays, crystallographic studies, and Nuclear Magnetic Resonance 
Spectroscopy have been employed to credibly demonstrate the crucial role of protein flexibility in 
ligand binding and to also give insights on biomolecular structures [43]. However, the notably huge 
expense, extensive computational labor and the static view portrayal of biomolecular systems 
prompted the search for alternative approaches such as computational techniques. Developed in the 
later part of the 1970s [44], Molecular Dynamics, has proven to be a viable technique [45,46] by 
reducing the computational complexity and cost associated with existing techniques  through the 
incorporation of simple Newtonian equations based approximations in the prediction of atomic 
motions [45]. There are two main types of simulation techniques, namely, Monte Carlo and Classical 
MD simulation amidst other recently synthesized techniques [26]. The Monte Carlo method relies on 
probabilities by creating large numbers of configurations and transitioning from one state to the other 
in a specific statistical manner [47]. In an Classical MD simulation, trajectories of atoms and 
molecules are generated by mathematically solving the Newton’s equation of motion for a system of 
interacting particles, in which forces between the particles and potential energy are defined by 
molecular mechanics force fields [48]. Trajectories specifies the particle position and velocity varies 
with time [49]. The preference of Classical MD to Monte Carlo is attributed to its ability to permit 
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time-dependent response and rheological properties amongst other dynamical properties [43]. In 
performing a Classical MD, the positions and velocities of particles, the force field and boundary 
conditions must be initially considered. The mathematical equation employed is described as follows; 
 
                 �࢏ = ࢓࢏ ࢊ૛࢘࢏ሺ࢚ሻࢊ࢚૛                                                                                                       (Eq. 3.6.1) 
Where is the particle position vector is represented as ri(t). The time-evolution is represented as t, 
while m denotes is the mass of the particle. The interacting force on thee particle is represented as 
Fi. 
 
 
3.7 Molecular Dynamics Post analysis 
A data set consisting of the coordinates and velocities of particles in a simulated system, referred to 
as MD trajectories [50] are generated after a given period of simulation. These trajectories can be 
analyzed using various post-dynamic computational tools. For the purpose of the studies reported in 
this thesis, post-dynamics analyses tools employed enabled the determination of; relatives binding 
free energies, three-dimensional conformations and configurations, and to determine the state of 
thermodynamic equilibrium of the biomolecular system [51]. 
3.7.1 Systems’ stability 
3.7.1.1  Convergence 
Convergence of a given system is attained when the system assumes a state of equilibrium [52,53]. 
This state of equilibrium is graphically depicted when the curve assumes a plateau shape [54]. As an 
empirical description of protein dynamics, convergence is based on fluctuation of bond angles and 
the vibrations of bond angles during protein unfolding [52]. Convergence vouch the accuracy and 
reproducibility of a given MD trajectory [52,55] and also gives insights on whether the simulated 
system achieves an energetically stable conformation.  
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3.7.1.2 Root Mean Square Deviation (RMSD) 
After a molecular dynamic simulation, trajectories generated can be analyzed to unravel the structural 
equilibrium of a given system by calculating the RMSD [56]. RMSD is calculated as the spatial 
difference between two static structures of the same trajectory [49].  Mathematically, it is expressed 
a follows;                ࡾࡹࡿ� = ቆ ∑�(ࡾ૚ −ࡾ૚૙)૛� ቇ૚૛                                                                                       (Eq. 3.7.1.2.1) 
N represents the total number of atoms in the complex. Ri denotes the vector position of the Cα 
atom in the reference conformation of particle i. This is calculated after aligning the structure to the 
initial conformation (O) using the least square fitting. 
The number of conformations for a given simulated biomolecular system can be deduced from how 
long that system took to achieve equilibration, an information that can be obtained from RMSD 
calculations [54]. RMSD may also unveil biomolecules that exhibit ‘open’ and ‘close’ conformations 
[54]. 
 
3.7.1.3 Radius of Gyration (RoG) 
Radius of Gyration as a post MD simulation analysis tool can be used to give insights into the 
compactness of the tertiary structure of a biomolecule [57,58]. The Radius of Gyration in a protein is 
calculated as the root mean square distance of the atoms from their common center of gravity [59]. 
RoG can unravel how folded or unfolded a biomolecule can be over a given simulation period [59]. 
The overall stability of a biomolecular structure over a given simulation period can also be deduced 
from the calculated RoG.  Mathematically, RoG is calculated as follows;  
                ࢘૛ࢍ࢟࢘ = (∑࢏−૚࢔ ࢃ࢏ሺ࢘࢏−࢘−ሻ૛)∑࢏−૚࢔ ࢃ࢏                                                                          (Eq. 3.7.1.3.1) 
The ri represents the position of the atom ith atom whiles r is the center weight of atom i. 
 
3.7.2 Conformational dynamics of System 
 
3.7.2.1 Root mean square fluctuation 
The fluctuation of the individual residues of a protein about an average position within a given 
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molecular simulation period is referred to the root mean square fluctuation (RMSF) [60]. RMSF 
unveils insights into the flexibility of various regions of the protein that parallels with the 
crystallographic ȕ-factors [60]. RMSF is mathematically calculated as follows;        �܀�܁۴� =  ሺ܀�܁۴�−܀�܁۴̅̅ ̅̅ ̅̅ ̅̅ ሻ�ሺ܀�܁۴ሻ                                                                           (Eq. 3.7.2.1.1) 
RMSFi represents the RMSF of the ith residue, from which the average RMSF is subtracted. This is 
then divided by the RMSF’s standard deviation to yield the resultant standardized RMSF. 
3.7.2.2 Binding free Energy Calculations 
The estimation of binding free energy calculations has become a very essential computational 
technique for understanding ligand-receptor interactions in drug design, determination of protein 
structures and protein-protein complex studies [61,62]. The most popular approaches employed in 
the estimation of the binding free energies of small ligands to biological macromolecules is the 
molecular mechanics energies combined with the Poisson–Boltzmann or generalized Born and 
surface area continuum solvation (MM/PBSA and MM/GBSA) methods [63–69]. Both techniques 
are employed after MD simulations of ligand-receptor complexes in which energies are averaged over 
from snapshots generated from MD trajectories to estimate the absolute total binding free energies 
[64]. They are typically based on molecular dynamics simulations of the receptor–ligand complex 
and are therefore transitional in both accuracy and computational effort between empirical scoring 
and strict alchemical perturbation methods [63]. MM/PBSA and MM/GBSA methods have been 
applied successfully to study a wide variety of problems[62,70,71]. For each snapshot, binding free 
energy is calculated for each molecular component (complex, receptor, and ligand), and the total 
ligand binding free energy is estimated as follows: 
                                                      ΔGbind = Gcomplex – Greceptor – Gligand (1)                       (Eq. 3.7.2.2.1) 
                                                               ΔGbind = Egas + Gsol – TΔS (β)                           (Eq. 3.7.2.2.2) 
                                                                  Egas = Eint + Evdw +Eele (3)                              (Eq. 3.7.2.2.3) 
                                                                    Gsol = GGB/PB + GSA (4)                                 (Eq. 3.7.2.2.4) 
                                                                          GSA = ȖSASA (5)                                   (Eq. 3.7.2.2.5) 
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Egas shows the gas-phase energy; Eint is internal energy; while Eele and Evdw represents the electrostatic 
and Van der Waals interactions, respectively. The solvation free energy, denoted by Gsol represents 
the solvation free energy and can be decomposed into polar and nonpolar contribution states. The 
polar solvation contribution, GGB/PB, is determined by solving the GB/PB equation, whereas, GSA, the 
nonpolar solvation contribution is estimated from the solvent accessible surface area (SASA) 
determined using a water probe radius of 1.4 Å. T and S correspond to temperature and total solute 
entropy, respectively. 
 
3.7.2.3 Residue Interaction Network 
The exploration of the amino acids that make up a protein as well the amino acid-amino acid 
interactions that exist in the protein is an essential approach in unveiling very important molecular 
insight into the structural and functional dynamics of the protein [72]. Residue Interaction Network 
(RIN) as computational post-dynamics analysis tool makes it possible to visualize and comprehend 
the complex inter-residue interaction [70,71]. In the studies reported in this thesis, RIN was employed 
to unravel the impact of single active site mutation on the overall conformational and structural 
dynamics of Mtb when singly bound with Rifampin and upon co-binding with Rifampin and DAAPI. 
In the visual display of each RIN, amino acid were each represented by a node while inter-residue 
interactions were represented by edges [73]. Using plugins such as RINalyzer [73], Cytoscape [74] 
and NetworkAnalyser [75]. RIN was performed displaying all the various amino acid and their 
respective interactions. Visualization was done by integrating Cytoscape with UCSF chimera. 
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Abstract 
Background: Amidst the current global challenge of anti-microbial resistance, RNA 
polymerase remains a paramount therapeutic target for Tuberculosis. Dual binding of 
Rifampin and a novel compound, DAAPI, demonstrated the suppression of Rifampin 
resistance. However, a paucity of data elucidating the structural mechanism of action of this 
synergistic interaction prevails.  
Methodology/Results: Molecular dynamic simulations unraveled the synergistic inhibitory 
characteristics of DAAPI and Rifampin. Co-binding induced a stable protein, increased the 
degree of compactness of binding site residues around Rifampin and subsequently an 
improved  binding affinity towards Rifampin.  
Conclusions: Findings established a structural mechanism by which DAAPI stabilizes 
Mycobacterium tuberculosis RNA polymerase, thus suppressing Rifampin resistance. This 
study will assist toward  the design of novel inhibitors to combat resistance associated with 
tuberculosis. 
 
Keywords: Tuberculosis therapy, Rifampin-resistance, Mycobacterium tuberculosis, 
thermodynamics binding energy, RNA polymerase  
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1. Introduction  
Tuberculosis (TB), caused by Mycobacterium Tuberculosis (Mtb), is the leading cause of 
morbidity from an infectious disease worldwide [1]. Despite the persistent research being 
conducted on a global scale towards designing effective anti-resistant small drug molecules, 
Mtb’s defense mechanism is equally evolving resulting in drug resistance. Resistance can 
occur due to a number of reasons, including possible genetic mutations upon bacterial 
replication [2]. The bacteria’s survival strategies against current therapeutic regimens has 
given rise to fatal strains that have now become resistant to most available therapies. 
In many countries such as South Africa, Mtb may join forces with immuno-compromising 
HIV/AIDS, thus creating an incurable and lethal co-infection [3]. It is therefore imperative 
to map out new strategies in the design of TB inhibitors that will be effective in overcoming 
resistance and be able to bind with a high affinity to an enzymatic target, thus structurally 
inhibiting Mtb indefinitely. 
Of the various Mtb therapeutic targets, the DNA-dependent RNA polymerase (RNAP) plays 
one of the most crucial roles in bacterial RNA synthesis [4–7]. Structurally, Mtb RNAP has 
five subunits which make up its core. These subunits are required for the elongation step of 
transcription [8]. Also, Mtb RNAP has a sixth σ-subunit (σ factor) that plays a crucial role in 
promoter recognition and transcription initiation [8]. Amongst the prominent front-line anti-
TB drugs is Rifampin [9–11]. By binding to its active site on the RNAP, Rifampin functions 
through a steric occlusion mechanism, inhibiting transcription and preventing the extension 
of 2-3 nucleotide RNA products [10–12]. In spite of  RIF’s initial therapeutic efficacy against 
TB, the drug has now become ineffective to some Mtb strains due to the introduction of 
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evasive alterations on key target enzymes during the replication and transmission of Mtb. In 
2016, the World Health Organization (WHO) reported an annual occurrence of as many as 
600,000 new cases of Rifampin resistance with 2015 recording an estimated 480,000 
Rifampin resistance TB cases. It is evident that Rifampin-resistance intensifies the array of 
challenges already associated with TB infection [1,13,14], thus supporting the crucial need 
to explore alternative strategies that will combat resistance and pave the road toward 
discovering a cure for TB.  Synergistic inhibition/dual inhibition has been previously proven 
over time to be an effective approach when facing the challenge of drug resistance [15–17], 
and hence can be explored.  
The first crystal structure of Mtb RNAP was recently released in complex with RIF and a 
novel class of experimentally validated Mtb RNAP inhibitors called Nα-aroyl-N-aryl-
phenylalaninamides (AAPs). These novel inhibitors uniquely bind to a separate hydrophobic 
pocket on Mtb RNAP, a site totally different from the binding site of Rifampin. Experimental 
findings demonstrated a synergistic effect when a prototype of these novel inhibitors, DAAPI 
and Rifampin are co-bound at their respective pockets, suppressing Rifampin resistance and 
inhibiting bacterial growth [18].  
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Figure 4.1: X-ray crystal structure of Mtb RNAP showing binding active sites (A) and bound 
(B) of RIF and DAAPI 
In this study we have divulged, for the first time, a structural mechanism of inhibition of Mtb 
RNAP using a synergistic approach. By employing a wide range of extensive molecular and 
bioinformatics tools, we define and compare Mtb RNAP’s structural and dynamic 
characteristics when bound as a dual inhibitor system. Furthermore, the comprehensive 
description of the conformational adaptations of RNAP’s structural machinery offers vital 
insights into preventing RIF resistance, as well as provides a binding landscape to assist in 
the design of novel inhibitors with improved therapeutic properties on the Mtb RNAP. 
2. Computational Methods 
2.1 Systems’ Preparation  
In performing the MD simulation, X-ray crystal structures of  Mtb RNAP were derived from 
the Protein Data Bank (PDB) with their respective PDB codes as follows; free RNAP (PDB: 
5UHA), RNAP in complex with Rifampin (PDB: 5UHB), RNAP in complex with D-AAP1 
(PDB: 5UHE) and RNAP in complex with both Rifampin and D-AAP1 (PDB: 5UHG) [18]. 
The Mtb RNAP and 3-D structures of Rifampin and D-AAP1 were prepared using the UCSF 
Chimera software package [19]. Lin et al (2017) reported conclusive experimental evidence 
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that co-administration of Rifampin and D-AAP1 bound at independent hydrophobic pockets, 
result in additive antibacterial activity and also suppresses the emergence of RIF resistance. 
A 50ns molecular dynamics (MD) simulation was performed on four prepared systems 
(APO, RIF, DAAPI and RIFDAAPI). Per our knowledge, this study is the longest MD 
simulation involving Mtb RNAP.  
2.2 Molecular Dynamic (MD) Simulations 
The AMBER14 package [20,21] was used to perform a 50ns MD simulation for all systems. 
In handling Mtb RNAP, the FF14SB AMBER force field was used. The restrained 
electrostatic potential in the ANTECHAMBER was used to compute partial atomic charges 
for Rifampin and DAAPI [22]. Na+ and Cl- which served as counter ions  were added to 
neutralize our enzyme using the LEAP module of AMBER14. The Leap module was also 
used to add hydrogens atoms to Mtb RNAP. Each systems was enclosed within an 8 Å box 
of TIP3P water molecules ensuring that all portions of the enzymes or enzyme complexes 
were covered by the water molecules throughout the simulation period. All systems were 
minimized in two separate minimization stages. The first minimization incorporated a 
restraint potential of 100 kcal/mol Å2  and was performed over the steepest descent 
minimization of 1000 cycles. The second minimization was also performed over the steepest 
descent minimization of 1000 cycles but without a restraint potential.  All systems were then 
heated from 0K TO 300K for 50ps in the canonical ensemble (NVT) in which all solutes 
atoms were restrained at a force constants of 10 kcal/mol Å2 . All systems were subsequently 
equilibrated at 300K for 500ps in the isothermal, isobaric ensemble (NPT) at constant 
pressure of 1 bar in which all constraints were removed . This pressure was maintained using 
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the Berendsen barostat. To restrain all atoms that were covalently bonded to a hydrogen, 
SHAKE algorithm  was incorporated. Without restraints, a 50ns MD simulation was 
conducted for all systems using the NPT ensemble.  
2.3 Post-Dynamic Analysis 
The trajectories generated after MD simulations were each saved every 1ps and were 
subsequently analyzed using the CPPTRAJ module of  the AMBER14 package. 
2.3.1 Binding free energy calculations 
The Molecular Mechanics/Generalized-Born Surface Area (MM/GBSA) [23] technique was 
used to calculated the binding free  energy of Rifampin and DAAPI in all systems. A total of 
5000 snapshots were generated from the 50ns trajectory. Using the approach below, the 
binding free (ΔG) were estimated. ∆�ୠi୬ୢ = �ୡ୭୫୮୪ୣ୶ − �୰ୣୡୣ୮୲୭୰ − �୪igୟ୬ୢ                                         ሺͳሻ ∆�ୠi୬ୢ = Egୟୱ + �ୱ୭୪ −     ܶ∆ܵ                                                             ሺʹሻ Egୟୱ = Ei୬୲ + E୴ୢ୵ + Eୣ୪ୣ                                                                   ሺ͵ሻ �ୱ୭୪ = �G୆ + �S୅                                                                                   ሺͶሻ �S୅ = γ�A�A                                                                                           ሺͷሻ 
Where  ∆�ୠi୬ୢ  is a summation of gas phase, Egୟୱ and the solvation energy, �ୱ୭୪ less the 
entropy (T∆S) term . The, Egୟୱ is obtained by a summation of the internal energy Ei୬୲ , 
electrostatic  energy Eୣ୪ୣ and the van der Waals energy, E୴ୢ୵ generated from systems. The 
total solvation energy is calculated  by a summation of the total energy contributions of polar 
states (GGB) and non-polar states (GSA) . GSA is calculated using the solvent accessible surface 
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area (SASA), generated by 1.4 Å radius water probe. By solving the GGB equation, the energy 
contributions of polar states can determined. S represented the total entropy of the solute 
while T represented temperature. Final energy per-residue decomposition were also 
calculated using the MMGBSA method [24]. 
3. Results and Discussion 
 
3.1 Systems’ stability 
Systems’ stability was evaluated by calculating the root mean square deviation (RMSD) for 
all four systems. The C-α atoms of all systems, with the exception of the RIF system, reached 
convergence and hence achieved stability after approximately 20ns (Figure S1). The 
flexibility of amino acids residues for all systems; APO, DAAPI, RIF and RIFDAAPI, were 
evaluated and compared by calculating  the root mean square fluctuation (RMSF) of the Mtb 
RNAP backbone [25]. The “1750-β000” region of the RIF system showed greater flexibility 
due to the obvious fluctuation of unbound residues at this region, as it encloses the DAAPI 
active site. Increased fluctuation was observed in the region that encompassed the active site 
of Rifampin  (residues “100-700’’). However, in the co-bound system, there was a decrease 
in residue fluctuation in this same region.  
It can be deduced from the systems’ stability analyses that there is an improvement in 
structural stability of Mtb RNAP protein structure from when it is unbound, to when bound 
with Rifampin alone and then finally achieving highest stability upon co-binding as depicted 
in figure 4.2.  
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Figure 4.2: Schematic depiction of Mtb RNAP complex stability increase upon binding of 
Rifampin and DAAPI. 
3.2 Thermodynamic binding landscape in RIF and DAAPI co-inhibition 
To gain an understanding into the energy dynamics of Rifampin binding to Mtb RNAP alone,  
and upon co-binding with DAAPI, the relative binding free energies were calculated using 
MM/GBSA method [23]. The binding free energy of the Rifampin when bound alone was 
calculated to be -49 kcal/mol while binding free energy for DAAPI when bound alone was -
21.61 kcal/mole as shown in Fig 4.3 and Table 4.1. Binding free energies for Rifampin and 
DAAPI when co-bound on Mtb RNAP were also calculated as follows; Rifampin (–51.41 
kcal/mol) and DAAPI (-16.01 kcal/mol).  Interestingly, as shown in figure 4.3, there is an 
binding free energy of Rifampin when co-bound with DAAPI. This is could be an indication 
that inhibitory potency of DAAPI increased the binding affinity of Rifampin to Mtb RNAP 
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and hence could possibly be the basis for the predicted suppression of Rifampin resistance in 
the presence of DAAPI[18]. This is further corroborated by the increase in van der Waals 
interactions as shown in figure 4.3 and Table 4.1. 
Table 4.1: Binding free energy of  DAAPI and RIF bound alone and when co-bound to Mtb 
RNAP 
 ENERGY COMPONENT (KCAL/MOL) 
 
 
INDIVIDUALLY  
 ΔEvdw ΔEele ΔGgas ΔGsolv ΔGbind 
 DAAPI 
-23.31  0.30 -33.35 0.65 -56.660.67 35.040.48 -21.610.34 
 RIF 
-59.35 0.37 -38.310.63 -97.670.65 47.720.44 -49.940.41 
       
CO-BOUND        
 DAAPI 
-25.79  0.28 -11.45 0.31 -37.250.44 21.240.29 -16.010.29 
 RIF 
-63.58 0.39 -22.590.54 -86.180.69 34.760.42 -51.410.55 
 
 
 
 
 
 
 
 
 
Figure 4.3: Binding free energy of Rifampin (RIF) in the absence and presence of DAAPI 
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Although thermodynamics revealed that co-binding of Rifampin and DAAPI improved 
binding affinity of Rifampin,  it would be misleading to rely on these findings alone [26]. As 
result, we  employed the Radius of gyration to give further molecular insights on the 
flexibility and compactness of residues involved in the binding of Rifampin. 
3.3 Compactness of Rifampin  active site residues in the presence and absence of DAAPI 
We calculated the Radius of Gyration (RoG) of the active site residues of Rifampin to explore 
the impact of the co-binding on them. Radius of gyration demonstrates the compactness of 
protein structures, unveiling insights into complex changes in the molecular structure[27]. 
With RoG we unraveled the flexibility or compactness of the selected active site residues 
throughout the simulation. When Rifampin was bound alone, active site residues showed a 
distinguishably higher RoG over the 50ns simulation, with an average RoG of 11.61Å. This 
portrayed a less compact structure when compared with the dual system. 
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Figure 4.4: Comparative compactness of Rifampin binding site residues of Mtb RNAP in 
the presence and absence of DAAPI. 
 
However, a demonstrably lower RoG was observed in the co-bound system (10.93Å). This 
decrease in RoG indicates an increase in compactness of the active site residues (Figure 4.5). 
It can therefore be deduced that the presence of DAAPI impacted a level of rigidity on 
Rifampin active site residues, translating into an increased stability in the binding of 
Rifampin. This was validated by the increased binding affinity of Rifampin in the co-bound 
system as elucidated above. It also confers with the experimentally demonstrated synergistic 
effects generated upon co-binding of Rifampin and DAAPI [18]. 
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3.4 Energy analysis of RIF and DAAPI binding sites’ residues 
To portray the collective drug-binding landscape at atomistic level, the binding energy 
contribution from each active site residues of DAAPI and RIF was calculated, thus the per-
residue binding footprints using the MM/GBSA method. Table S1 and S2 shows the 
decomposed energies contributed by each active site residue for RIF and DAAPI 
respectively. However figure 4.5 shows highest energy contributing active sites residues and 
a representation of the interaction of these ligands with their respective binding site residues. 
As evident from Figure 4.5(A), residues ARG 427(-3.133 kcal/mol), SER 429(-1.604 
kcal/mol) and PHE 412(-4.1.30 kcal/mol) were found to contribute the most towards the 
binding of RIF, while ARG 1958(-4.578) and ILE 1975 (-1.121 kcal/mol) with optimal 
residue energy contributions ΔGbind > -1kcal/mol. These collectively contributed to the total 
binding free energies of Rifampin and DAAPI calculated in the thermodynamics. 
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Figure 4.5. Total residue binding free energies, van der Waals (vdW), electrostatic (Elec) 
energy components for residues with binding energies > -1 kcal/mol and corresponding 
ligand interactions for Rifampin (RIF) (A) DAAPI (B)  
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4. Conclusions 
Computational analytical tools were used to understand the co-inhibitory mechanism of RIF 
and a novel inhibitor, DAAPI, toward the suppression of RIF resistance. DAAPI, a recently 
synthesized inhibitor has been experimental proven to subdue the emergence of RIF 
resistance, while still incorporating an additive antibacterial activity. To this end, 
comparative MD simulations and analyses were performed in order to explore the binding 
landscape and structural features associated with synergistic dual inhibition. Results 
demonstrated that the co-bound Mtb RNAP system induced a more stable, compact protein 
structure, when compared to systems in which RIF and DAAPI are bound alone. 
Thermodynamic calculations indicated that DAAPI exerts some level of stability and 
stronger RIF-Mtb RNAP interactions, complemented by compactness of RIF binding site 
residues when co-bound with DAAPI and an increased van der Waals interactions. As a 
result, the calculated binding free energy of RIF in the presence of DAAPI was higher 
compared to when bound alone as elucidated in the thermodynamics. This mechanism could 
explain the suppression of RIF resistance as previously reported. Per-residue energy 
decomposition analysis revealed that, amino acid residues: SER 429, PHE 412 and LEU 431 
are key residues that largely contribute to the binding of RIF, while ARG 1958 and ILE 1975 
were vital to the binding of DAAPI. This knowledge will contribute to a greater 
comprehension of binding landscapes of these inhibitors at a molecular level. Based on this 
study, RIF and DAAPI demonstrate a synergistic mechanism of inhibition. 
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Abstract 
Rifampin resistance has been a large contributor to the global epidemic of antimicrobial 
resistance, thus dampening the existing efforts being made to control the crisis of 
Tuberculosis. Previous studies that attempted to provide insights into the structural 
mechanism of Rifampin resistance did not utilize the X-ray crystal structure of 
Mycobacterium tuberculosis RNA polymerase due to its unavailability. In this study, we 
provide an atomistic mechanism behind Rifampin resistance when the recently resolved 
crystal structure of Mycobacterium tuberculosis RNA polymerase is subjected to a single 
active site mutation. We also identify and rationalize the structural interplay of this mutation 
upon co-binding of Rifampin with a novel inhibitor, DAAPI. The mutation distorted the 
overall conformational landscape of Mycobacterium tuberculosis RNA polymerase, resulting 
in a reduction of binding affinity of Rifampin and an overall shift in the residue interaction 
network of Mycobacterium tuberculosis RNA polymerase and upon single binding. 
Interestingly, co-binding with DAAPI, though impacted by the mutation exhibited improved 
Rifampin binding interactions amidst a distorted residue interaction network. Findings offer 
vital conformational dynamics and structural mechanisms of mutant enzyme-single ligand 
and mutant enzyme- dual ligand interactions which could potentially shift the current 
therapeutic protocol of TB infections, thus aiding in the design of novel Mycobacterium 
tuberculosis RNA polymerase inhibitors with improved therapeutic features against the 
mutant protein. 
Keyword: Mycobacterium Tuberculosis RNA polymerase, Co-inhibition, Rifampin 
resistance  
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1. Introduction 
The rapid evolution of infectious pathogenic agents leading to the emergence of resistant 
variants is currently a dilemma for the scientific community. This burden has not been any 
different regarding Tuberculosis (TB). The emergence of resistant Mycobacterium 
Tuberculosis (Mtb) strains is currently a global crisis and has subsequently complicated the 
existing efforts being made to control the global Tuberculosis epidemic [1,2]. As a result, TB 
currently ranks above HIV as the leading cause of morbidity from an infectious disease [2]. 
The resistance to Rifampin, a major first-line anti-TB drug [3–5], accounts for a significant 
proportion of the total global statistics on Mtb drug resistance. In a 2016 report by the WHO, 
an estimated number of 480,000 TB cases in 2015 were either infected with Rifampin 
resistant strains or patients developed resistance in the course of antibiotic treatment [2,6]. 
Rifampin functions by binding to the β subunit of the DNA dependent enzyme, RNA 
polymerase (RNAP) to prevent the extension of RNA beyond 2-3 nucleotides through steric 
occlusion mechanism [7–9], hence inhibiting transcription. Due the critical role played by 
Rifampin in the treatment of TB, resistance to Rifampin is a potential threat to current TB 
control measures. Synergistic inhibition from combination of Rifampin and other drugs have 
been reported to be an effective approach in targeting  of drug resistance [10–12], 
nonetheless, it could be explored further. 
Rifampin resistance is largely attributed to a spontaneous single amino acid mutation 
occurring at the Rifampin-Resistant Determining Region, a region with three distinct loci 
near the center of the β-subunit of RNAP [6,13]. Clinical isolation and identification of most 
rifampin resistant strains have reportedly shown amino acid substitutions at positions 
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occurring in the Rifampin-cluster I of the rpoB gene [6]. However amongst these residue 
positions, mutations S531L and H526Y accounts for about 41% and 36% respectively of 
Rifampin resistance [7,14–17].  
To give the first direct structural and molecular insights responsible for Rifampin resistance, 
Molodtsov et al in 2016 [6] synthesized crystal structures of E. coli RNAP together with 
some clinically isolated mutants and concluded that each mutant elicited different structural 
and/or surface electrostatic potential changes which make the RIF binding interface less 
favorable for binding RIF [6].  Also, based on a 10ns simulation, Nusrath et al [18] reported 
RIF resistance due to changes in binding interactions with RIF as a result of mutation of some 
active site residues. However, Nusrath et al used a homology modelled Mtb RNAP with 
RNAP of Thermus thermophiles as a template. 
In light of the short falls of these previous studies, notably (i) lack of crystal structure of Mtb 
RNAP and (ii) short molecular dynamic simulations, our study aims to overcome these 
shortfalls by incorporating more reliable, valid and reproducible techniques. We therefore 
report the first account of the molecular interaction between Rifampin and a mutant RNAP 
generated from a recently crystallized Mtb RNAP, in a much longer molecular dynamic 
simulation. Using sophisticated molecular techniques and bioinformatics tools, we also 
attempt to give a molecular interpretation of the possible influence of a mutation on the active 
site of Rifampin on the synergistic effect yielded when rifampin is co-administered with a 
novel RNAP-targeted inhibitor, DAAPI [19]. Conclusions from this study will offer vital 
conformational dynamics and structural mechanisms of the mutant- single ligand and mutant-
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dual ligand interactions that will aid in the design of novel Mtb RNAP inhibitors with 
improved therapeutic features against the mutant target proteins. 
 
 
 
 
Figure 5.1. 3-D structure of Mtb RNAP depicting RIF’s active site mutation 
(SER429LEU429). 
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Figure 5.2: 2D structure of DAAPI and Rifampin.  
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2. Computational Methods 
 
2.1 Preparation of Systems 
The X-ray crystal structures of Mtb RNAP were extracted from the Protein Data Bank (PDB) 
with the following PDB codes; Wild type Mtb RNAP (PDB: 5UHA), Wild type Mtb RNAP 
in complex with Rifampin (PDB: 5UHB) and Wild type Mtb RNAP in complex with both 
Rifampin and DAAPI (PDB: 5UHG) [19] . The proteins were then prepared following 
standard procedure using the UCSF Chimera software package [20]. A point mutation was 
introduced at position 429 located on the Rifampin binding site, where Serine (SER 429) was 
replaced with Leucine (LEU 429) (from S to L) to obtain the mutant structures of Mtb RNAP 
using Chimera [20]a. The 3-D structures of the RIF and DAAPI were derived from their 
complexes with RNAP and prepared on Chimera software as well. We then performed a 50ns 
molecular dynamics simulation of our prepared systems, the longest simulation involving an 
Mtb RNAP to our best of knowledge. The systems included; RIF (wild type Mtb in complex 
with RIF), mRIF (mutated Mtb RNAP in complex with Rifampin), mRIFDAAPI (mutated 
Mtb RNAP in complex with Rifampin and DAAPI) and RIFDAAPI (wild Mtb RNAP 
complex with Rifampin and DAAPI). 
2.2 Molecular Dynamic (MD) Simulations 
MD simulations were performed on all systems over a 50ns period to establish the effect of 
mutation S431L on the binding of Rifampin in the presence or absence of a separately co-
bound inhibitor, DAAPI. The  MD simulation was carried out using the graphics processing 
unit of the PMEMD engine incorporated in the AMBER14 suite [21,22]  following 
established in-house protocols reported in many of our previous studies[23–28] . Due to 
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missing residues (E1-M206), all residues after M206 were renumbered as per the LEAP 
module. This resulted in the adjustment of the residue of interest from S431L to S429L.  
2.3 Post-Molecular Dynamic Simulation Analysis 
Coordinates generated for each system after simulation were each saved at an interval of 1ps. 
Generated MD trajectories were then analyzed. RMSD, RMSF, thermodynamic calculations 
RIN, Hydrogen bonds and occupancy analysis  as post-MD simulations analysis techniques 
were carried out using the CPPTRAJ and  PTRAJ modules incorporated in the AMBER 14 
suite. 
2.3.1 Binding affinity analyses 
The estimation of binding free energy in this study was performed using the Molecular 
Mechanics/Generalized Born Surface Area (MM/GBSA) method [29].  A method employed 
in many of our previous reports [24,25,27,30,31]. 5000 snapshots were taken from the 50ns 
trajectory of each simulated system to average the binding free energies .  
2.3.2 Residue Interaction Network exploration 
 A representative snapshot at the end of the 50ns MD simulation trajectory of each  simulated 
system was utilized to generate the residue interaction network (RIN). Cytoscape [32] and 
the RINalyzer plugin [33] were employed to visualize generated RIN. In a RIN, protein 
residues denoted by nodes and while their corresponding non-covalent interactions are 
represented by edges. Edges are denotes an interaction types such as hydrogen bonds 
amongst others. The NetworkAnalyzer [34] plugin of Cytoscape was used to analyze the 
node degree and node connectivity. The RINalyzer plugin was then used to analyze the 
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closeness centrality and shortest path betweenness of complex topological parameters in  
network.  
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3. Results and Discussion 
 
3.1 Conformational stability of wild and mutant singly bound/co-bound Mtb RNAP 
The stability of the 3D backbones atoms of the Mtb RNAP were unraveled by assessing the 
root mean square deviation (RMSD), with respect to the starting structures during the period 
of simulation. The RMSD of the simulated systems graphically monitored their convergence  
(Figure S1). It was observed that all mutant systems (mRIF, mRIFDAAPI) appeared to have 
reached convergence at an elevated energy compared to the wild systems (RIF, RIFDAAPI) 
(Figure S1). This could possibly indicate that the single active site mutation affected the 
overall conformational stability of Mtb RNAP by increasing the number of conformations of 
the protein. 
3.2 Exploration of Residue Interaction Network in singly/co-bound mutant and wild-type 
Mtb RNAP 
Exploring and analyzing the residue interaction network in wild or mutant Mtb RNAP when 
bound to Rifampin, DAAPI or both unveiled further insights into the structural, functional 
and conformational dynamics of role of individual residues [35–37]. Previous studies from 
our group has successfully applied RIN to characterize the implication of residue mutation 
to drug resistance [24,25]. Using the representative protein structures from our 50ns MD 
simulation, we investigated the interplay of single active mutation, S429L, with the 
neighboring network of residues that interacted with our residues of interest.  
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Figure 5.3: Residue Interaction Network around mutation site (S429L) of Mtb RNAP upon 
single binding with Rifampin alone (A and B) and co-binding with Rifampin and DAAPI (C 
and D). 
Upon a close exploration of RIN in the singly bound systems (Figure 5.3A and 5.3B), it was 
obvious that the mutation altered the overall network of residues in the mutated system 
(mRIF) compared to the wild (RIF). Residues that interacted with Ser 429 in the singly bound 
wild-type wild were different from those interacting with Leu 429 upon the mutation. In the 
wild, Ser 429 interacted with Val 354, Ser 155 and Glu 2508 (Figure 5.3A). However, upon 
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the mutation to Leu, Leu 429 interacted with Ser 407, Ser 150 and Pro 433 (Figure 5.3B). It 
can also be observed that Ser 429 forms more H-bond interactions with neighboring residues 
as compared to Leu 429 in the mutated system corroborating with the decreased binding 
affinity elucidated in thermodynamics analysis (Table 5.1). 
In the co-bound systems (Figure 5.3C and 5.3D), it could be observed that regardless of the 
residue network distortion caused by the mutation, there was a visible increase in the number 
of interactions that Leu 429 was engaged in when compared with Ser 431. Notable amongst 
such interactions were van der Waals interaction. Mutation in the co-bound generally 
improved the stability of Rifampin-Mtb RNAP interactions besides changing the landscape 
of Mtb RNAP and the atomic interactions between the Rifampin-Mtb RNAP and the key 
residues. These could have played critical roles in strengthening the binding of Rifampin in 
the presence of DAAPI. This confers with higher binding affinity of Rifampin upon co-
binding than when singly bound as described in the thermodynamics analysis, amidst the 
single active site mutation. 
 
3.3 Binding Energy profile of Rifampin to singly/co-bound Mtb RNAP upon single active 
site mutation.  
To further understand the implication of the single active mutation on the binding of 
Rifampin to Mtb RNAP alone or when co-bound with DAAPI, we estimated the binding free 
energy of Rifampin in all the simulated complexes over the 50ns simulation period using the 
MM/GBSA [29] technique (Table 5.1).   
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Table 5.1: MM/GBSA-based binding free energy profile of Rifampin in all simulated 
systems 
System Energy components 
(kcal/mol) 
 ઢ۳ܞ܌ܟ ઢ۳܍�܍ ઢ۵�܉� ઢ۵�ܗ� ઢ۵܊�ܖ܌ 
RIF 
 
mRIF 
 
mRIFDAAPI 
 
RIFDAAPI   
-59.35 0.37 
 
-61.06 0.41 
 
-57.880.49 
 
  -63.58±0.39 
-38.310.63 
 
-22.07 0.88 
 
-40.911.00 
 
-22.59±0.54  
-97.670.65 
 
-83.131.06 
 
-98.791.07 
 
-86.18±0.69 
47.720.44 
 
39.530.72 
 
51.460.80 
 
34.76±0.42 
-49.940.41 
 
-43.590.58 
 
-47.340.52 
 
-51.41±0.55 
    
 
The calculated binding free energy (ઢ۵܊�ܖ܌) of Rifampin in all simulated systems were as 
follows; RIF and RIFDAAPI (singly and co-bound wild systems), 49.940.41 kcal/mol and 
-51.41 kcal/mol respectively, the singly and co-bound mutated systems (mRIF and 
mRIFDAAPI) were -43.590.58 kcal/mol and -47.340.52 kcal/mol respectively.  
There was an overall reduction in the binding affinity in the mutant systems due to the 
mutation, which impaired the binding of Rifampin, thus reducing its effectiveness against the 
mutant RNAP. This corroborates with the experimental evidence, which indicates that 
mutation of any residue at the Rifampin resistance-determining region impairs the binding 
of Rifampin [38,39]. The decrease in binding affinity of Rifampin when singly bound to 
mutant Mtb RNAP(mRIF) system could be attributed to the notable decrease in the 
electrostatic interactions, while the binding energy of the co-bound mutant system 
(mRIFDAAPI) system could be due to the significant decrease in the van der Waals 
interaction (Table 5.1). Interestingly, however, when comparing the binding free energy of 
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Rifampin upon co-bounding and single binding in the mutant systems’, it can be observed 
that the co-bound mutant system had a higher binding free energy (-47.34 kcal/mol) than the 
singly bound mutant system (-43.59 kcal/mol). This suggests that regardless of the mutation 
in the binding site of Rifampin on Mtb RNAP, co-binding with DAAPI could have exerted 
some synergistic property which induced a stronger binding of Rifampin as experimentally 
predicted by Lin et al [19]. 
 
Hydrogen bonds (H-bonds) Patterns 
The stability and structural integrity of Mtb RNAP-ligand interaction is majorly dependent 
on H-bond interactions [40,41]. H-bond formation between residues is vital in monitoring of 
the conformation of Mtb RNAP. In singly bound systems, the wild Mtb RNAP system (RIF) 
showed the highest average of 1289.97 H-bond interactions when compared with the singly 
bound mutated system (mRIF) which showed an average of 1283.23 H-bond interactions 
(Figure 5.4A) over the 50ns simulation period. However, it was interesting to note that upon 
co-binding with DAAPI, the mutant system (mRIFDAAPI) had a higher average number of 
H-bond interactions (1313.19) than the co-bound wild system (RIFDAAPI), which showed 
an average number of 1293.72 H-bond interactions (Figure 5.4B).   
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Figure 5.4: Number of inter-molecular hydrogen bond (H-bond) interactions observed 
during the molecular dynamic simulation in singly bound (A) and co-bound (B) systems in 
both mutated and the wild systems. 
 
The decrease in H-bond formation when Rifampin was singly bound to the mutated Mtb 
RNAP could be attributed to the destabilization of H-bond interactions triggered by the single 
active site mutation, S429L. The mutated residue, Serine, is a hydrophilic polar residue that 
participated in hydrogen bonding with LEU152 (Table S1). Mutation of Serine to a 
hydrophobic residue, Leucine, possibly induced localized conformational changes in Mtb 
RNAP resulting in a  to the loss of established H-bonds. The decrease in the number of H-
bond interaction led to structural distortions and conformational changes, which ultimately 
affected the binding of Rifampin [42], hence the decreased binding free energy of Rifampin 
in the mutant system as shown in the calculated thermodynamics (Table 5.1). The relatively 
higher average H-bonds interactions in the co-bound mutated Mtb RNAP when compared to 
the singly bound mutant Mtb RNAP suggest that the co-bound mutant gained extra stability 
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amidst the mutation and could be attributed to the presence of DAAPI, which possibly 
influenced the increase in formation of H-bond interactions amongst residues. This 
corroborates with the increased residue-residue interactions in the RIN analyses of the co-
bound mutant enzyme coupled with a subtle increase in binding free energy of Rifampin 
from -43.59 kcal/mol when singly bound to -47.34 kcal/mol upon co-binding with DAAPI 
amidst the mutation. This also confers with the experimental prediction of the suppression of 
the emergence of Rifampin in the presence of DAAPI [19].  
 
3.2 Flexibility and Compactness of Residues of singly bound/co-bound  mutant and wild 
Mtb RNAP over 50ns  
The conformational properties of a Mtb RNAP, as a protein is largely influenced by the 
individual amino acids that form the building block of the protein [43,44]. Interactions of 
active site residues with either Rifampin, DAAPI or both may to trigger conformational 
modifications in the structure of Mtb RNAP which could distort its function [44]. 
Understanding the fluctuations of the individual residues of a Mtb RNAP upon the binding 
of Rifampin, DAAPI or both with or without mutation gives insight into the overall flexibility 
of the various regions of Mtb RNAP that corresponds to its crystallographic ȕ factors [45]. 
The Root Mean Square Fluctuation (RMSF) enabled the exploration of structural dynamics 
upon ligand binding in the various systems and was calculated from the MD trajectories 
generated after the MD simulation (Figure 5).  
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Figure 5.5: The Root Mean Square Fluctuations (RMSF) of mutant S429L (black) with 
respect to wild type Mtb RNAP (red) for 50 ns trajectory using Cα atoms upon single binding 
and co-binding. The region marked with blue circle encompasses the residue of interest 
involved and shows increase fluctuation in S429L for both singly bound and co-bound 
systems. 
 
Overall, the mutated Mtb RNAP systems (mRIF, mRIFDAAPI) showed marked flexibility 
of residues in protein structures, thus depicting visible residue fluctuations (Figure 5.5) when 
compared with the wild systems (RIF, RIFDAAPI). This clearly indicates that the single 
active site mutation destabilized the entire protein structure of Mtb RNAP in both singly 
bound and co-bound states. There was also a notable increase in fluctuation of residues 
79 
 
around the region of mutation compared to relatively more compact residues around the same 
region in the wild systems upon single binding and co-binding. This visible increase in 
flexibility of active site residues upon mutation consequently affects the binding affinity of 
Rifampin.  
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4. Conclusion 
In this study, we utilized computational techniques to explore the ramifications of a single 
active site mutation on the binding of Rifampin to the recently resolved crystal structure of 
Mtb RNAP. We provide multidimensional insights on the impact of this mutation in a co-
bound system with the novel inhibitor, DAAPI. Molecular dynamics simulations, 
thermodynamics calculations, hydrogen bond interactions and RIN analyses were employed 
to achieve our objectives. Results showed that, single active site mutation decreased the 
binding affinity of Rifampin, decreased the H-bond interactions and induced structural 
rearrangement around the mutant site in Mtb RNAP when Rifampin is bound alone. 
However, amidst the structural rearrangement around the mutation site, there was an 
improved interaction amongst neighboring residues coupled with an increased H-bond and 
van der Waal interaction upon co-binding with Rifampin and DAAPI.  Also, Rifampin bound 
stronger to Mtb RNAP in combination with DAAPI than when bound alone amidst the single 
active site mutation. Results are consistent with the earlier reports of  the drastic effect of 
active site mutation on the binding of Rifampin to Mtb RNAP, while conferring with the 
experimental prediction of the suppression of Rifampin resistance upon co-binding of 
Rifampin with DAAPI. Findings also provide critical molecular insights for future design of 
novel Mtb RNAP inhibitors to eradicate drug resistance in TB. 
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 CHAPTER 6 
 
Conclusion and Future Perspectives 
 
6.1 Conclusions 
The emergence of Rifampin resistance has contributed immensely to global TB epidemic with an 
increase in new reported cases in the last few years. As a result, finding viable approaches of 
combating Rifampin resistance has become extremely paramount. Over these last few years anti-
Rifampin resistance approaches have been proposed, nonetheless, researchers are still working 
tireless in the design therapeutic approaches and potential small drug molecules that can be co-
administered with Rifampin to curb the menace of Rifampin resistance. 
 
The major aims of this thesis were to unravel molecular insights into the suppression of the emergence 
of resistance to Rifampin by a novel Nα-aroyl-N-aryl-phenylalaninamides (AAPI) prototype inhibitor 
co-bound to Mtb RNAP; and to also provide a molecular understanding of the interplay of  a single 
active site mutation on the emergence Rifampin resistance amidst single binding of Rifampin or upon 
co-binding with both Rifampin and the novel inhibitor prototype, DAAPI. Results from this work 
confirmed the following conclusions: 
1. Co-binding with both Rifampin and DAAPI induced a more stable and compact Mtb RNAP than 
when Mtb RNAP was singly bound to either Rifampin or the novel inhibitor, DAAPI. 
2. Thermodynamic calculations indicated that DAAPI exerts some level of stability and stronger 
Rifampin-Mtb RNAP interactions, which was complemented by a notable compactness of 
Rifampin binding site residues and increased van der Waals interactions upon co-binding. 
3. The calculated binding free energy of Rifampin in the presence of DAAPI was higher compared 
to when bound alone as elucidated in the thermodynamics possibly explaining reason for the 
suppression of RIF resistance as previously experimentally predicted.  
4. Per-residue energy decomposition analysis revealed that, amino acid residues: SER 429, PHE 
412 and LEU 431 are key residues that largely contribute to the binding of RIF, while ARG 1958 
and ILE 1975 were vital to the binding of DAAPI. This knowledge will contribute to a greater 
comprehension of binding landscapes of these inhibitors at a molecular level. Based on this 
study, Rifampin and DAAPI demonstrate a synergistic mechanism of inhibition 
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5. Single active site mutation decreased the binding affinity of Rifampin, decreased the H-bond 
interactions and induced structural rearrangement around the mutant site in Mtb RNAP when 
Rifampin is bound alone. 
6. Amidst the structural rearrangement around the mutation site, there was an improved interaction 
amongst neighboring residues coupled with an increased H-bond and van der Waal interaction 
upon co-binding with Rifampin and DAAPI. 
7. Rifampin bound stronger to Mtb RNAP in combination with DAAPI than when bound alone 
amidst the single active site mutation. Results are consistent with the earlier reports of the drastic 
effect of active site mutation on the binding of Rifampin to Mtb RNAP, while also conferring 
with the experimental prediction of the suppression of Rifampin resistance upon co-binding of 
Rifampin with DAAPI. 
Overall, this study has provided essential conformational and structural molecular insights into the 
design and development of new TB therapeutic approaches as well novel anti-TB inhibitors through 
molecular modeling and CADD 
 
6.2 Future Scope and beyond 
Using computational tools, the studies reported in this thesis complemented and justified previously 
reported experimental findings, providing reliable molecular insights which can be employed in 
future studies. Computational perspective unraveled in these studies opened up some future scopes, 
which can serve as the bases for future research. 
 
1. Findings from this thesis supports that co-binding of Rifampin and the novel inhibitor, 
DAAPI  on Mtb RNAP suppresses the emergence of Rifampin resistance as previously 
predicted experimentally. Further research could still, however, be carried out to provide 
potential pharmacophoric features in the design and development of new small molecules 
inhibitors that can singly target Mtb RNAP to suppress anti-TB resistance. Single acting 
drugs will reduce the risk of toxicity and will be relatively less expensive than the co-
administration of two separate drugs.  
 
2. To further examine the validity of the simulation and parameters proposed for describing the 
systems studied, the simulation could be performed in triplicate of longer periods of 
molecular dynamic simulations for each system. The triplicate of the run can be use evaluate 
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parameters proposed and to further understand the impact of co-binding Rifampin and 
DAAPI on the emergence of Rifampin resistance as well the revealing the impact of single 
active site mutation.  
 
 
91 
 
APPENDIX 
APPENDIX A 
 
Supplementary Documents for submitted paper: Clement Agoni, Ramharack P . and Soliman M 
E (2017) Co-inhibition as a Strategic Therapeutic Approach to Overcome Rifampin Resistance 
in TB Therapy: Atomistic Insights, Future Medicinal Chemistry, Manuscript ID: FMC-2017-
00197  
 
APPENDIX B 
 
Supplementary Documents for submitted paper: Clement Agoni, Ramharack P. and Soliman M 
E (2017) Synergistic Interplay of The Co-administration of Rifampin And Newly Developed 
Anti-TB Drug: Could It Be a Promising New Line of TB Therapy?, Receptor and Signal 
Transduction, Manuscript ID: LRSTS-2017-0113  
 
 
Co-inhibition as a Strategic Therapeutic Approach to Overcome 
Rifampin Resistance in TB therapy: Atomistic insights 
 
 
Supplementary Material: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure S1. The Cα root mean square deviations (RMSD) of the backbone atoms relative 
to the starting minimized structure over 50ns simulation for APO, RIF, DAAPI and RIF-
DAAPI. 
 
Figure S2. RMSF of C-α atoms for APO, DAAPI, RIF and RIFDAAPI over 50ns of 
simulation. 
 Table S1: Decomposition of the relative binding free energies on per residue basis for 
the Rifampin-Mtb RNAP complex. 
Residue ΔEvdw ΔEelec ΔGnonpolar ΔGpolar ΔGbinding 
ARG 146 -0.218 ± 0.048 -1.220 ± 0.415 -0.007 ± 0.009 1.596 ± 0.408 0.150± 0.114 
THR 406 -0.089 ± 0.038 -0.126 ± 0.087 -0.006 ± 0.016 0.277 ± 0.104 0.056 ±0.037 
SER 407    -0.280 ± 0.073 -0.132 ± 0.174 -0.027 ±   0.012 0.413 ± 0.251 -0.025±0.091 
GLN 408 -2.102 ± 0.434 0.241 ± 0.690 -0.320 ± 0.040 0.839 ± 0.599 -1.341±0.503 
LEU 409 -0.272 ± 0.054 0.254 ±   0.050 0.000 ± 0.000 -0.329 ± 0.075 -0.347±0.075 
SER 410 -0.584 ± 0.145 0.370 ±   0.191 -0.038 ± 0.015 -0.073 ± 0.213 -0.325±0.102 
PHE 412 -1.260 ± 0.675 -4.909 ± 0.701 -0.335 ± 0.023 2.373± 0.331 -4.130±0.586 
MET 413 -0.730 ± 0.106 -0.431 ± 0.102 -0.003 ± 0.003 0.836 ± 0.193 -0.328±0.189 
ASP 414 -1.950 ± 0.242 1.868 ± 0.713 -0.142 ± 0.020 -0.516 ± 0.855 -0.740±0.606 
GLN 415 -0.097 ± 0.012 0.048 ± 0.034 0.000 ± 0.000 0.026 ± 0.052 -0.024±0.035 
HIE 424 -1.034 ± 0.235 1.196 ± 0.397 -0.048 ± 0.011 -0.652 ± 0.285 -0.538±0.338 
ARG 427 -1.789 ± 0.588 -11.515 ± 1.521 -0.225 ± 0.026 10.396 ± 1.070 -3.133±0.806 
SER 429 -0.179 ± 0.520 -4.498 ± 0.677 -0.033 ± 0.014 3.107 ± 0.194 -1.604±0.321 
LEU 431 -2.847 ± 0.474 -0.054 ± 0.219 -0.285 ± 0.047 0.839 ± 0.217 -2.348±0.516 
GLY 432 -0.958 ± 0.318 0.106 ± 0.153 -0.101 ± 0.030 0.385 ± 0.227 -0.568±0.352 
ARG 438 -0.445 ± 0.347 0.936 ± 0.629 -0.086 ±   0.090 -0.207 ± 0.859 0.199± 0.315 
THR 461 -0.050 ± 0.012 -0.163 ± 0.081 0.000 ± 0.000 0.340 ± 0.087 0.128± 0.037 
PRO 462 -0.500 ± 0.215 0.255 ± 0.118 -0.082 ± 0.026 0.012 ± 0.160 -0.315±0.278 
GLU 463 -0.260 ± 0.161 -1.559 ± 0.586 -0.025 ± 0.029 1.920 ± 0.856 0.076 ±0.281 
GLY 464 -0.033 ± 0.017 0.082 ± 0.044 -0.000 ± 0.000 -0.026 ± 0.036 0.023± 0.027 
PRO 465 -0.106 ± 0.094 0.133 ± 0.068 -0.003 ± 0.012 -0.052 ± 0.080 -0.028±0.067 
ASN 466 -0.947 ± 0.751 0.151 ± 0.976 -0.161 ± 0.136 0.712 ± 1.193 -0.245±0.444 
ARG 586 -0.827 ± 0.258 0.286 ± 0.494 -0.124 ± 0.044 1.065 ± 0.407 0.400± 0.249 
GLN 587 -0.132 ± 0.058 0.086 ± 0.120 -0.018 ± 0.028 0.147 ± 0.107 0.083± 0.054  
HIP 653 -0.881 ± 0.271 0.264 ± 0.559 -0.177 ± 0.029 1.258 ± 0.573 0.464± 0.435 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S2: Decomposition of the relative binding free energies on per-residue basis for 
the DAAPI-Mtb RNAP complex. 
 
Residues ΔEvdw ΔEelec ΔGnonpolar ΔGpolar ΔGbinding 
LYS 819 -0.296 ±0.499 -6.244± 3.980 -0.173± 0.134 6.697 ±3.795 -0.015± 0.683 
ARG1958 -1.909± 0.784 -12.471±1.359 -0.473±0.067 10.276±1.179 -4.578± 1.007 
PRO1959 -0.231± 0.136 -0.096 ± 0.161 -0.033± 0.025 0.351± 0.264 -0.009 ± 0.077 
VAL1960 -0.292 ± 0.216 0.176 ± 0.077 -0.032 ± 0.031 -0.112±0.042 -0.259± 0.213 
LYS1961 -0.032 ± 0.023 0.574 ± 0.292 -0.000 ± 0.002 -0.476±0.259 0.066 ± 0.032 
SER1962 -0.015 ± 0.011 0.113 ± 0.044 -0.000 ± 0.000 -0.104±0.040 -0.006 ± 0.011 
THR1969 -0.038 ± 0.022 -0.093± 0.099 -0.000 ± 0.001 0.113 ± 0.103 -0.018± 0.021 
LEU1971 -0.823 ± 0.513 -0.222 ± 0.425 -0.225± 0.149 0.500 ± 0.624 -0.770 ±0.479 
GLU1972 -0.376 ± 0.293 -2.091 ± 0.527 -0.058± 0.049 2.306 ± 0.666 -0.219 ± 0.207 
PHE1974 -0.221 ± 0.255 0.155 ± 0.069 -0.047 ± 0.076 -0.079±0.116 -0.193± 0.250 
ILE1975 -0.959 ± 0.447 0.276 ± 0.120 -0.226 ± 0.094 -0.212±0.105 -1.121± 0.499 
HIS1978 -0.182 ± 0.189 0.107± 0.074 -0.034 ± 0.047 0.108 ± 0.228 -0.001± 0.067 
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Figure S1: Comparative root mean square deviation of mutated and unmutated systems upon 
single binding of Rifampin (A) and upon co-binding with DAAPI (B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table S1: Hydrogen bond occupancy of interacting active site residues of Rifampin in the wild 
singly bound RIF system 
 
H-bond 
Acceptor 
H-bond 
Donor 
Frames Occupancy 
 (%) 
Average 
distance (Å) 
Average angle 
(degree) 
GLU_460@O THR _564H 51218 98 2.691 164.4725 
ASP_414@O SER_420@H 49795 95 2.6798 164.1854 
VAL_149@O ARG_352@H 43667 84 2.8222 156.2499 
SER_429@O LEU_152@H 39931 77 2.8528 162.2017 
ARG_146@O PHE_139@H 37463 72 2.8735 163.767 
GLN_408@O GLN_411@H 36926 71 2.8592 164.305 
GLN_415@O SER_651@H 36616 70 2.7474 154.7249 
ARG_586@O ASN_416@H 28731 55 2.8594 156.9693 
LEU_431@O GLN_151@H 27193 52 2.8683 158.6173 
MET_413@O ASN_652@H 22997 44 2.8831 161.8032 
LEU_409@O GLN_411@H 21170 41 2.8741 146.3306 
SER_410@O ARG_146@H 18535 36 2.8195 157.1721 
THR_461@O ASN_583@H 18225 35 2.8662 160.3019 
MET_413@O GLN_415@H 16657 32 2.8534 145.4704 
ASN_466@O LEU_469@H 15364 29 2.8936 149.7248 
GLU_463@O GLU_463@H 13599 26 2.8103 150.6947 
ARG_427@O SER_150@H 11365 22 2.7575 155.2029 
HIP_653@O HIP_724@H 11161 21 2.7923 150.2511 
SER_407@O LEU_409@H 7930 15 2.925 156.2667 
ARG_438@O TYR_2443H 1888 4 2.7435 161.8803 
PRO_462@O GLY_464@H 1436 3 2.8886 145.2237 
GLY_464@O ASN_466@H 724 1 2.8639 148.5496 
HIE_424@O ARG_427@H 679 1 2.9171 148.1715 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table S2: Hydrogen bond occupancy of interacting active site residues of Rifampin in the 
mutated singly bound mRIF systems 
 
H-bond 
Acceptor 
H-bond Donor Frames Occupancy    
(%) 
Average distance    
(Å) 
Average angle  
(degree) 
ASP_414@O SER_420@H 51498 96 2.6634 164.3344 
SER_410@O ARG_146@H 40928 77 2.8249 153.7175 
SER_407@O SER_410@H 38174 72 2.6779 162.8938 
GLN_411@O VAL_149@H 35000 66 2.8558 164.3801 
MET_413@O GLN_415@H 34835 65 2.8326 147.6212 
GLU_460@O SER_472@H 27373 51 2.7076 160.6573 
GLN_408@O GLN_411@H 27085 51 2.8511 160.663 
GLN_411@O VAL_147@H 26990 51 2.879 156.6565 
GLY_432@O GLY_435@H 23506 44 2.8739 149.299 
GLU_463@O GLU_463@H 23375 44 2.8186 152.4317 
LEU_409@O GLN_411@H 20707 39 2.8585 144.7838 
THR_461@O ASN_583@H 17024 32 2.865 156.8918 
ARG_146@O PHE_139@H 15682 29 2.8859 149.9139 
GLN_415@O LYS_136@H 13208 25 2.8348 156.9629 
LEU_431@O GLN_151@H 11045 21 2.8482 158.4389 
LEU_429@O GLN_151@H 9978 19 2.8482 161.5036 
HIE_424@O ARG_427@H 9665 18 2.9137 155.7397 
ARG_427@O SER_150@H 9122 17 2.8902 148.9958 
ASN_466@O LEU_469@H 3095 6 2.9024 147.4206 
PRO_465@O ARG_446@H 2384 4 2.8093 156.9627 
GLY_464@O ASN_466@H 1925 4 2.801 144.8855 
ARG_438@O GLN_1050@H 1319 2 2.8586 153.5162 
GLN_587@O LYS_865@H 555 1 2.8253 158.0322 
  
 
 
 
 
 
 
 
 
 
 
 Table S3: Hydrogen bond occupancy of interacting active site residues of Rifampin in the 
mutated co-bound mRIFDAAPI system 
 
H-bond 
acceptor 
H-bond 
donor 
Frames Occupancy 
(%) 
Average distance (Å) Average angle 
(degree) 
ASP_414@O ARG_586@H 42953 80 2.8136 160.106 
GLY_432@O GLY_435@H 31455 57 2.8685 148.5645 
LEU_429@O LEU_152@H 28082 52 2.8784 160.2063 
ASN_466@O ILE_470@H 23971 45 2.883 156.5121 
LEU_431@O GLN_151@H 17412 32 2.8605 156.2142 
MET_413@O ASN_652@H 16329 31 2.8725 161.0883 
GLN_415@O THR_655@H 16023 30 2.7309 160.6464 
GLU_463@O GLU_463@H 13978 26 2.8196 151.1642 
PRO_465@O ILE_467@H 11920 22 2.8904 145.2289 
LEU_409@O VAL_149@H 8876 17 2.8977 157.4278 
SER_410@O ARG_146@H 8603 16 2.8299 154.4312 
SER_407@O SER_410@H 8582 16 2.9033 151.681 
PHE_412@O HIE_424@H 4541 8 2.835 147.5039 
ARG_427@O SER_150@HG 4258 8 2.7567 154.5606 
GLN_408@O GLN_408@H 4212 8 2.8466 147.9696 
PRO_462@O GLY_464@H 3165 6 2.8546 145.9462 
THR_461@O ASN_583@H 1816 3 2.8704 156.5311 
GLN_587@O ASN_416@H 1393 3 2.9009 143.1098 
HIE_424@O ARG_427@H 1118 2 2.9292 158.4036 
ARG_438@O ALA_441@H 1055 2 2.9276 156.69 
ASN_466@O ARG_438@H 805 2 2.8421 155.8878 
 
 
 
 
 
 
 
 
 
 
 Table S4: Hydrogen bond occupancy of interacting active site residues of Rifampin in the wild 
co-bound RIFDAAPI system 
 
H-bond 
Acceptor 
H-bond 
donor 
Frames Occupancy 
(%) 
Average 
distance (Å) 
Average angle 
(degree) 
SER_429@O  LEU_152@H 45061 89 2.8221 161.642 
LEU_431@O  GLN_151@H 42712 85 2.8328 162.4605 
GLN_411@O VAL_147@H 39170 78 2.8585 164.6051 
GLY_435@O ARG_2515@H 34708 69 2.8434 156.9005 
LEU_428@O  GLY_471@H 31810 63 2.8679 157.117 
ARG_426@O   LEU_473@H   30994 61 2.875 164.3169 
GLU_460@O SER_561@H 30825 61 2.6395 164.5575 
ASP_414@O        SER_420@H 28594 57 2.6835 163.0455 
GLY_432@O GLY_435@H 26042 52 2.868 146.9922 
VAL_149@O  GLN_151@H 18941 38 2.8254 147.734 
ARG_586@O ASN_416@H 17845 38 2.8582 152.341 
GLU_463@O ASN_466@H 16677 33 2.8441 159.5455 
MET_413@O GLN_415@H  16036 32 2.8193 146.7779 
HIE_424@N ASP_414@H 15776 31 2.9252 157.215 
ASN_466@O  LEU_469@H 15191 30 2.8967 151.335 
LEU_409@O  VAL_149@H  14222 28 2.8999 161.9313 
SER_407@O SER_410@H 12432 25 2.9129 161.3599 
THR_461@O ASN_583@H 8550 17 2.8557 161.4456 
HIP_653@O HIP_724@H 8496 17 2.7966 148.1274 
ARG_427@O SER_150@H 7492 15 2.7185 155.8104 
GLY_464@O  ILE_467@H  6425 13 2.9088 161.8643 
SER_410@O ARG_146@H 5887 12 2.8938 149.5393 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
